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Abstract:
Motivated by a genome-wide association study (GWAS) to discover risk variants for the
progression of Age-related Macular Degeneration (AMD), I develop a computationally effi-
cient copula-based score test, in which the association between bivariate progression times is
explicitly modeled. Specifically, a two-step estimation approach with numerical derivatives
to approximate the score function and information matrix is proposed. Both parametric and
weakly parametric marginal distributions under the proportional hazards (PH) assumption
are considered. Extensive simulation studies are conducted to evaluate the Type I error
control and power performance of the proposed method. Further I extend this work to gene-
based tests through the functional linear regression approach, which models the variants
(within the same gene region) as a function of their physical positions. A robust variance
estimator for bivariate time-to-event data under functional linear model is also proposed.
Simulation studies are conducted to evaluate the Type I error control and power perfor-
mance of the proposed method. Finally, we apply our method on a large randomized trial
data set, Age-related Eye Disease Study (AREDS), to identify progression risk variants and
gene regions for AMD progression. The top variants identified in the ARMS2 gene on chro-
mosome 10 show differential progression profiles for different genetic groups, which are useful
in characterizing and predicting the risk of progression for patients with moderate AMD.
v
Public health significance: The application of the proposed methods jointly models the
progression profiles in both eyes, which has not been done in any of the previous studies
of AMD progression. The findings provide new insights about the genetic causes on AMD
progression from single variants to genes, which will be critical for establishing novel and
reliable predictive models of AMD progression to accurately identify high-risk patients at an
early stage.
vi
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1.0 INTRODUCTION
1.1 MOTIVATING EXAMPLE
Our research is motivated by a genome-wide association study (GWAS) on identifying risk
variants for progression of a bilateral eye disease – Age-related Macular Degeneration (AMD).
AMD is a common, polygenic, and progressive neurodegenerative disease, which is a leading
cause of blindness in the developed world (Swaroop et al., 2009; The Eye Diseases Prevalence
Research Group, 2004). The overall estimated prevalence of any AMD was 6.5% in the
United States, with a 95% confidence interval [5.5%, 7.6%], and the prevalence of late AMD
was 0.8%, with a 95% confidence interval [0.5%, 1.3%] (Klein et al., 2011).
The age-related eye disease study (AREDS) was a multi-center, controlled, randomized
clinical trial of AMD sponsored by National Eye Institute. It was designed to assess the
clinical course and risk factors for the development and progression of AMD. In this cohort,
participants were longitudinally followed up to 12 years to examine the progression of the
disease (Age-Related Eye Disease Study Research Group, 1999). The study collected DNA
samples of consenting participants and performed genome-wide genotyping. The objective
of our study is to discover risk variants and genes for AMD progression using the AREDS
dataset.
1.2 GENOME-WIDE ASSOCIATION STUDY
With wide-spread availability of high-throughput genotyping technology, large scale GWAS
become a powerful tool to discover risk variants for complex diseases. One ultimate goal of
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these association studies is to uncover the biological underpinnings of disease susceptibility
(Wang et al., 2005). Results of such studies can subsequently lead to better understanding
of the disease process and the development of improved strategies for disease prevention and
treatment.
The most common GWAS approach is based on case-control samples, which compares
a group of diseased individuals with healthy individuals to discover significant variants as-
sociated with the disease (Wu et al., 2010; The Wellcome Trust Case Control Consortium,
2007). Another popular GWAS approach studies the quantitative traits of individuals such
as gene expression or biomarker concentration (Cho et al., 2009). More recently, GWAS on
time-to-event data have become increasingly popular to study the progression or survival
profiles of certain diseases. For example, Azzato et al. (2010) performed a GWAS of survival
after diagnosis of breast cancer. Pillas et al. (2010) conducted a GWAS for time to first
tooth eruption. Ioannidis et al. (2010) did a thorough review of cancer-related GWAS.
1.3 GENETIC STUDIES OF AMD PROGRESSION
Both common and rare variants associated with AMD risk (i.e., whether or not to develop
the disease) have been identified in multiple large-scale case-control association studies (Chen
et al., 2010a; Fritsche et al., 2013, 2016). However, the genetic causes of AMD progression
have not been well studied.
Recently, several studies evaluated the effects of a few known AMD risk variants on its
disease progression (Seddon et al., 2009, 2014). These studies analyzed only one eye per
subject (e.g., the faster progressed eye). More recently, Sardell et al. (2016) and Ding et al.
(2017) evaluated a set of known AMD risk variants on progression using both eyes with
a robust marginal Cox model, where the between-eye correlation was taken into account.
All the existing studies on AMD progression only analyzed a small set of known AMD risk
variants. To the best of our knowledge, no large-scale studies have been performed to discover
the variants associated with AMD progression.
2
      To understand  the  genetic underpinning of  progression of  this  bilateral  disease, our ﬁrst
objective is to develop a computationally efficient test procedure for bivariate time-to-event 
data to perform GWAS for single markers. The second objective is to extend this single 
marker test procedure to gene-based association analysis.
3
2.0 BACKGROUND
2.1 TIME-TO-EVENT DATA ANALYSIS
Time-to-event data analysis, also known as survival analysis, is a branch of statistics for
analyzing the expected duration of time for an event to happen. In life science applications,
such events can be death, disease/tumor progression, and etc.
Define a random variable T as the time from the beginning of an observation period to
the occurrence of an event. The survival function S(t) describes the probability of event
happens prior to time t. Specific to time-to-event analysis, when the follow-up time is not
long enough to capture the event, or patients drop off during the follow-up, call it censored.
Effects of different censoring schemes have been widely studied. In this work, we consider the
right censored scenario when censoring time is independent of event time. Define a random
variable for censoring time as C and censoring indicator as ∆ = I(T ≤ C). The observed
time is denoted by Y = min(T,C). The observed data are
D = {(Y,∆) : Y = min(T,C),∆ = I(T ≤ C)}.
The cumulative hazard H(t) and the instantaneous hazard λ(t) are two useful functions
in survival analysis, where S(t) = exp(−Λ(t)) = exp(− ∫ λ(t)dt). In time-to-event data
analysis, the most commonly used approach is the Cox proportional hazards model (Cox,
1972) which models the instantaneous hazards as a regression function of covariates. Another
commonly used approach is the accelerated failure time model (Wei, 1992), which directly
models the transformed survival time as a function of covariates.
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2.2 METHODS FOR BIVARIATE TIME-TO-EVENT DATA
The standard techniques to analyze time-to-event data are based on the assumption that
event times are independent of each other. However, this assumption can be violated when
the study units are paired such as twins, married couples or bilateral objects such as eyes
in ophthalmology studies. In the presence of the dependence between the event times,
multivariate survival analysis needs to be considered. Hougaard (2000) and Joe (1997)
provide thorough reviews and examples for multivariate survival analysis.
First, we introduce notation for bivariate time-to-event data. Assume there are n sub-
jects. Let (T1i, T2i) and (C1i, C2i), i = 1, ..., n, denote the bivariate failure times and censoring
times, respectively. Denote by X = (X1i, X2i) the risk factors for the ith subject. Assume
given the covariates X, (T1i, T2i) and (C1i, C2i) are independent. Then for each subject, we
observe
Di = {(Y1i, Y2i,∆1i,∆2i, X1i, X2i) : Yki = min(Tki, Cki),∆ki = I(Tki ≤ Cki), k = 1, 2}.
Let S(t1, t2) = P (T1 > t1, T2 > t2) denote the joint survival function for the bivariate
failure time (T1, T2) and let f(t1, t2) denote its corresponding density function. Denote by θ
all the parameters in S(t1, t2), then the joint likelihood for the observed data {Di}ni=1 can
be written as
L(θ;D = (Y1, Y2,∆1,∆2, X1, X2))
=
n∏
i=1
f(y1i, y2i|x1i, x2i)δ1iδ2i ×
[
−∂S(y1i, y2i|x1i, x2i)
∂y1i
]δ1i(1−δ2i)
×
[
−∂S(y1i, y2i|x1i, x2i)
∂y2i
](1−δ1i)δ2i
× S(y1i, y2i|x1i, x2i)(1−δ1i)(1−δ2i),
(2.1)
where (δ1i, δ2i) ∈ {(0, 0), (0, 1), (1, 0), (1, 1)}.
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2.2.1 Marginal model
The first approach for analyzing bivariate time-to-event data is a marginal method, which
was developed under the General Estimation Equation (GEE) framework. A robust sandwich
estimator from the estimating equation is used to estimate the variance-covariance matrix of
the regression parameter. For example, Wei et al. (1989) considered the semi-parametric Cox
model and proposed to estimate the regression parameter β under a working independence
assumption by which observations in each cluster are treated as independent of one another.
Assume the regression coefficients are the same across each margin. Define for each
margin k,
Yki(t) = I{Tki ≥ t}.
Then, under the Cox proportional hazards assumption, the bivariate partial score function
for β can be written as
U(β) =
2∑
k=1
n∑
i=1
Uki(β)
=
2∑
k=1
n∑
i=1
∆ki
{
Xki − S
(1)
k (tki; β)
S
(0)
k (tki; β)
}
, (2.2)
where S
(0)
k (t; β) =
∑n
i=1 Yki(tki) exp(βXki) and S
(1)
k (t; β) =
∑n
i=1 Yki(t) exp(βXki)Xki, k =
1, 2. Define βˆ to be the root of U(β) = 0. If the marginal Cox regression model is correctly
specified, n−
1
2U(β) is asymptotically normally distributed with mean zero and variance
B = E[U2ki(β)],
which, in practice, can be estimated by
Bˆ =
1
n
2∑
k=1
n∑
i=1
[U2ki(β)]|β=βˆ. (2.3)
In another form, variance of n−
1
2U(β) can expressed by
A = −E[∂Uki(β)/∂β]. (2.4)
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Note that (2.4) can be consistently estimated by
Aˆ = − 1
2n
2∑
k=1
n∑
i=1
∂Uki(β)/∂β|β=βˆ,
and robust inference is based on the variance Γˆ = Aˆ−1Bˆ(Aˆ−1)′. It is closely related to the
GEE methodology (Liang and Zeger, 1986). Lee et al. (1992) showed that βˆ was consistent
with n−
1
2 (βˆ − β)→ N(0,Γ), where Γ = A−1B(A−1)′.
A marginal model is useful when the main interest is to estimate the effect of covariates
on survival. By applying a “sandwich” estimator, it takes into account the fact that observed
event times are correlated. However, the strength of such correlations cannot be explicitly
modeled under this marginal approach.
2.2.2 Copula model
One of the earliest distribution families for modelling correlated bivariate measurements
is the copula family (Clayton, 1978), originated from Sklar’s Theorem (Sklar, 1959), in
which the joint distribution is modeled as a function of each marginal distribution together
with an association parameter. Copula function provides a parametric assumption about the
association between two correlated margins. A bivariate copula is a function defined as {Cη :
[0, 1]2 → [0, 1] : (u, v)→ Cη(u, v), η ∈ R}. Assume U and V are both uniformly distributed
random variables. The parameter η in the copula function describes the dependence between
U and V . By Sklar’s theorem (Sklar, 1959), one can model the joint distribution by modeling
the copula function and the marginal distributions separately. The theorem is stated as: if
marginal survival functions S1(t1) = P (T1 > t1) and S2(t2) = P (T2 > t2) for T1 and T2 are
continuous, then there exists a unique copula function Cη such that for all t1 ≥ 0, t2 ≥ 0,
S(t1, t2) = Cη((S1(t1), S2(t2)), t1, t2 ≥ 0.
Define the density function for Cη to be cη = ∂
2Cη(u, v)/∂ u∂ v, then the joint density
function of T1 and T2 can be expressed as
f(t1, t2) = cη(S1(t1), S2(t2))f1(t1)f2(t2), t1, t2 ≥ 0.
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The Copula function is robust in modeling various dependence structures and has nice prop-
erties. For example, the rank-based dependence measurement Kendall’s τ can be directly
obtained as a function of η in some copula models.
In this work, we focus on the Archimedean copula family, which is one of the most
popular copula families because of its flexibility and simplicity. A copula Cη belongs to an
Archimedean family if it can be expressed as:
Cη(u, v) = H(H
−1(u; η) +H−1(v; η)), 0 ≤ u, v ≤ 1.
H : [0,∞) → [0, 1] is the so-called generating function for Archimedean copulas. It is
continuous, strictly decreasing and convex satisfying H(0; η) = 0.
Two most frequently used Archimedean copulas in survival analysis are:
Clayton copula (Clayton, 1978)
Cη(u, v) = (u
−η + v−η − 1)−1/η, η ∈ (0,∞),
and
Gumbel-Hougaard copula (Gumbel, 1960)
Cη(u, v) = exp{−[(− log u)η + (− log v)η]1/η}, η ∈ [1,∞).
The Clayton copula models lower tail dependence in survival functions, while a Gumbel cop-
ula models upper tail dependence in survival functions. For a Clayton copula, the association
parameter η corresponds to Kendall’s τ as τ = η
η+2
. Thus, T1 and T2 are positively associ-
ated when η > 0 and are independent when η → 0. While for a Gumbel copula, τ = η−1
η
,
meaning T1 and T2 are positively associated when η > 1 and are independent when η = 1.
Figure 1 shows a visual example of how margins are correlated under the Clayton copula
with Weibull marginal distributions. The figure indicates that as Kendall’s τ increases, both
(T1, T2) and (S1, S2) become more linearly related.
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Figure 1: Marginal association on survival probability and event times under Clayton copula
with Weibull margins (no censoring).
Sk, Tk, k = 1, 2 are the survival functions and observed event times respectively.
Under the copula model, the joint likelihood function (2.1) can be rewritten as
L((η, S1, S2);D) =
n∏
i=1
[cη(S1(y1i|x1i), S2(y2i|x2i))f1(y1i|x1i)f2(y2i|x2i)]δ1iδ2i
×
[
−∂ Cη(S1(y1i|x1i), S2(y2i|x2i))
∂y1i
]δ1i(1−δ2i)
×
[
−∂ Cη(S1(y1i|x1i), S2(y2i|x2i))
∂y2i
](1−δ1i)δ2i
× Cη(S1(y1i|x1i), S2(y2i|x2i))(1−δ1i)(1−δ2i).
(2.5)
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One important characteristics for Clayton copula model is that the ratio of two condi-
tional hazards between T1 given T2 = t2 and T1 given T2 ≥ t2 is a constant, namely,
λ1(t1|T2 = t2)
λ1(t1|T2 ≥ t2) = 1 + η.
This ratio is also known as cross ratio (Clayton, 1978; Oakes, 1982), a popular depen-
dence measurement for multivariate survival data in addition to Spearman’s correlation and
Kendall’s τ .
2.2.3 Frailty model
Another popular approach for analyzing multivariate survival data is the frailty model,
which was originally proposed by Oakes (1982) and Vaupel et al. (1979). In this approach,
a common latent frailty variable, as a random effect, introduces the correlation between
survival times under Cox Proportional hazards model. The hazard function for each margin
for a given subject can be specified as,
λi,1(ti,1; β1|wi) = wiλ1(ti,1; β1)
λi,2(ti,2; β2|wi) = wiλ2(ti,2; β2),
where λ1(·) and λ2(·) are hazard functions for each margin. Here the frailty random variable
wi ∼ fρ(w) follows a prespecified distribution with parameter ρ. For example, Gamma and
positive stable distributions are commonly used distributions in practice. To obtain the joint
survival function, one can derive the two marginal survival functions by integrating out the
random effect,
S(t1; β1) =
∫ ∞
0
e−wΛ1(t1;β1)fρ(w)dw = Lp(Λ1(t1; β1))
S(t2; β2) =
∫ ∞
0
e−wΛ2(t2;β2)fρ(w)dw = Lp(Λ2(t2; β2)). (2.6)
Here Lp(·) is the Laplace transformation on the density function of the random frailty term
w.
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Assume the conditional independence of T1 and T2 given w, one can express the joint
distribution of T1 and T2 as
S(t1, t2; β1, β2|w) = S1(t1; β1|w)S2(t2; β2|w). (2.7)
Combining (2.6) and (2.7) the joint survival function can be explicitly written out as:
S(t1, t2; β1, β2) =
∫ ∞
0
S1(t1; β1|w)S2(t2; β2|w)fρ(w)dw
=
∫ ∞
0
e−w(Λ1(t1;β1)+Λ2(t2;β2))fρ(w)dw
= Lρ[L−1ρ (S1(t1; β1)) + L−1ρ (S2(t2; β2))]. (2.8)
2.2.4 Relationship between Archimedean copula model and frailty model
The marginal Archimedean copula model, Cα(u, v) = H(H
−1(u; η) + H−1(v; η)) and the
shared frailty model (2.8) are two approaches to model bivariate survival function P (T1 >
t1, T2 > t2). By integrating out the frailty variable, the joint survival function ends up being
the same as an Archimedean copula. There are some equivalencies between the two general
approaches.
From section 2.2.3, the joint survival function is derived as S(t1, t2) = L(Λ1(t1) + Λ2(t2))
with Λk(t) = L−1(Sk(t)). Thus one can write out the joint survival function as S(t1, t2) =
L[L−1(S1(t1)) + L−1(S2(t2))]. This form is the same as the form of an Archimedean copula
with a generating function equal to L−1.
For example, we compare the Gamma frailty model and Clayton copula. The density
function for a one-parameter Gamma distribution with mean 1 and variance η is
fU(u) =
u((1/η)−1) exp(−u/η)
η1/ηΓ(1/η)
.
The Laplace transformation of the Gamma frailty density is
L(s) = (1 + ηs)−1/η
and
L−1(s) = s
−η − 1
η
, η ≥ 0.
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Pluging into (2.8) the joint survival function becomes:
S(t1, t2) = [S1(t1)
−η + S2(t2)−η − 1]−1/η.
This is the same as the Clayton copula. A Similar relationship can be derived for Gumbel cop-
ula and positive stable frailty model with generating function H−1(s) = L(s) = exp(−s1/η).
For the estimation procedure, a two-stage approach proposed by Shih and Louis (1995)
are often used for solving a copula model. The frailty model is solved based on conditional
likelihoods. This may lead to different parameter estimates in real applications.
2.3 SINGLE MARKER TESTS IN GENETIC STUDIES
In typical genome-wide association studies, single marker tests are performed in most of
scenes. Such tests examine the association between a single nucleotide polymorphism (SNP)
and a trait once at a time. Among choices of single marker tests, the score test is usually
preferred than other types of likelihood-based tests, like the Wald test or the likelihood ratio
test (LRT) (Cantor et al., 2010; Sha et al., 2011). This is because in large scale screening,
the score test only needs to fit the model under the null (i.e., no SNP effect) rather than
fitting millions of (alternative) models, one for each SNP. Because of this feature, the score
test is computationally more efficient and stable compared to the Wald test and the LRT.
There are many readily available computer programs for conducting single marker GWAS
on quantitative, binary, count and censored traits.
2.4 GENE-BASED TESTS FOR TIME-TO-EVENT DATA
In genome-wide association studies, single variant test is powerful in detecting possible signals
across whole genome for common variants and variant with relatively large effect sizes.
However, there are some limitations when applying single variant test. For example, the
single variant test lacks of power to detect association with rare variants or variants with
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small effect sizes. In addition, most of the statistical approaches used for testing single
variants are not stable when the minor allele frequency is small. Therefore, there is an
increasing interest to develop new statistical methods to investigate the relationship between
rare variants and disease susceptibility (Wu et al., 2010; Lin et al., 2011; Gorlov et al., 2008).
2.4.1 Burden test
Burden test was first proposed by Li and Leal (2008) for binary traits for the purpose of
detecting association with rare variants for the common diseases. The general idea of the
burden test for genetic studies is based on collapsing rare variants in a genetic region to be a
summary variable, which is then used for testing the association with the phenotypes. Later
Han and Pan (2010) extended the work for censored traits under Cox proportional hazards
framework. The burden test has been demonstrated to be most powerful when all causal
variants have the same effect direction.
Define Xi to be non-genetic covariates and Gi to be the genotype for individual i. Assume
one is interested in testing the overall effect of m variants in a region. For censored traits,
under Cox proportional hazards assumption, the burden test can be formulated as:
λi(t) = λ0(t)e
Xiβ+GiWiγ,
where Wi is a pre-defined m × m diagonal weight matrix (e.g. a function of minor allele
frequency). β and γ are regression coefficients for non-genetic and genetic effects respectively.
Assume the effect sizes for all variants are homogeneous with γ = γ0, then the hypothesis
for testing the genetic effects can be written as:
H0 : γ0 = 0 vs. H1 : γ0 6= 0,
which is a burden test with the collapsed genetic burden score
∑m
j=1GijWjj, where Gij is
the jth element of vector Gi for individual i, and Wjj is the j the diagonal element of the
weight matrix W . All types of likelihood-based test like Wald, LRT and score test can be
performed.
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2.4.2 Sequence kernel association test (SKAT)
The sequence kernel association test (SKAT) was proposed by Wu et al. (2011), is usually
considered as a computationally efficient score test on variance component parameter to test
for association between genetic variants in a region and different types of traits. One of the
advantages of SKAT is it can quickly calculate p-values by fitting the null model containing
only the non-genetic covariates. When the linear kernel is used, the test statistic can be
expressed as a weighted sum of the statistics from single marker score test.
In 2014, Chen et al. (2014) extended SKAT to survival traits. With survival phenotypes
modeled by the Cox PH model, the hazard function can be written out as:
λi(t) = λ0(t)e
Xiβ+GiWγ,
where β is p fixed effects for the non-genetic covariates, γ is m random effects with mean 0
and variance σ2Im for the genotypes. W is a pre-define weight matrix. The SKAT formulates
the test hypothesis as:
H0 : σ
2 = 0 vs. H1 : σ
2 > 0.
The SKAT statistic is
Q = r′GWWG′r ∼
m∑
j=1
λjχ
2
1,j,
where Σ is the covariance matrix of the vector WG′r, r is the vector of martingale residuals
calculated from the null model, λj are the eigenvalues of Σ, and χ
2
1,j are independent χ
2
distributions with degree of freedom 1. Wu et al. (2011); Lin and Tang (2011) demonstrated
that SKAT is superior to other existing rare variant tests, especially in the presence of both
protective and detrimental rare variants.
2.4.3 Functional regression for time-to-event data
A limitation of the burden test and SKAT is the lack of effectively utilizing linkage disequi-
librium (LD) or in other words, correlation among genetic variants, effectively. Fan et al.
(2013) first introduced the idea of functional regression (FR) for testing associations between
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genetic variants and quantitative traits. The FR-based model treats the contribution of ge-
netic markers as a function of physical positions and a realization of a stochastic process.
Recently, Fan et al. (2016) extended this work to censored traits and applied the method on
AREDS dataset using only left eye information.
Assume in a genomic region, m variants are sequenced with ordered physical positions,
e.g., base pair positions, 0 ≤ u1 < ... < um. Let Gi = (gi(u1), ..., gi(um))′ denote the
genotype information and Xi = (xi1, ..., xip) denote a p × 1 vector of fixed effect of non-
genetic covariates for subject i. A FR-based Cox proportional hazards model can be written
as:
λi(t) = λ0(t) exp
(
X
′
iβ +
∫ 1
0
Gi(u)γ(u)du
)
, (2.9)
where λ0(s) is the baseline hazard function, and β is a p×1 vector of coefficients for fixed non-
genetic effect covariates. Gi(u) is the genetic variant function (GVF) and γ(u) is the genetic
effect function (GEF) at the position u. In practice, one can approximate the integration
part in (2.9) by a summation term
λi(t) = λ0(t) exp
(
X
′
iβ +
m∑
j=1
gi(uj)γ(uj)
)
. (2.10)
In both representation of (2.9) and (2.10), γ(u) is assumed to be smooth and can be
approximated using smoothing techniques like B-spline or Fourier spline (Ramsay et al.,
2009). Define a series of Bγ basis function by ψ(u) = (ψ1(u), ...ψBγ (u))
′ and a Bγ × 1
coefficient vector (γ1, ..., γBγ )
′, then γ(u) can be approximated by
γˆ(u) = (ψ1(u), ...ψBγ (u))(γ1, ..., γBγ )
′
. (2.11)
A standard test procedure to test whether the variants in a region are associated with
the outcome can be translated to test the null hypothesis:
H0 : γ1 = ... = γBγ = 0.
With a model specified using such a smoothing technique, instead of estimating m parame-
ters, we have only Bγ ( m in most cases) parameters to estimate.
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3.0 A COPULA-BASED SCORE TEST ON SINGLE MARKERS FOR
BIVARIATE TIME-TO-EVENT DATA
3.1 BACKGROUND
As discussed in section 1.2, fast development of high-throughput genotyping technology
makes single variant tests for each SNP widely applied in detecting genome wide associations
for disease phenotypes during the past decade. From the most commonly used case-control
setup to quantitative phenotypes, many statistical methods have been established. Motivated
by the study of identifying risk variants associated with AMD progression, with progression
times available for both eyes, a test procedure suitable for large-scale bivariate time-to-event
data is in need.
Three major approaches for dealing with bivariate censored data are reviewed in section
2.2 for their pros and cons. Given the objective of our study is to discover risk variants for
the progression of this bilateral disease, we propose to develop a test procedure based on
copula models, so that we can (1) assess the genetic effect on a marginal (population) level,
and (2) explicitly model the correlation strength while accommodating a very large number
of “clusters” (i.e., subjects).
In the GWAS setting, the score test is usually preferred, given it usually requires less
computing time, especially when the model fitting is time consuming. In this work, we
develop a computationally efficient copula-based score test procedure for analyzing bivari-
ate time-to-event data, and then apply it on AREDS data to identify significant variants
associated with AMD progression.
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3.2 SCORE TEST UNDER COPULA FRAMEWORK
We consider testing each single SNP in a GWAS setting. Specifically, we are interested in
testing the null hypothesis that, whether a given SNP is associated with disease progression,
after adjusting for other risk factors. In this work, we consider the marginal distributions
under the Cox PH assumption. We then further denote by S0 = (S01, S02) the baseline
survival functions for T1 and T2, and β = (βg, βng) the regression coefficients, where βng are
the coefficients of non-genetic risk factors and βg is the coefficient of the SNP. In this work,
we assume the regression coefficients β are the same for T1 and T2, which is scientifically
plausible for the bilateral eye disease we consider here. However, the method can be easily
generalized to the situation where each Tk has its own regression coefficients.
Denote by a p × 1 vector θp×1 = (β′, α′, η) the full parameter set for the copula model,
where β′ = (βg, βng)′ denotes the regression coefficients, α′ = (α1, α2)′ denotes the parameters
in S0k(·), η is the association parameter. We are interested in testing whether or not βg = 0.
Thus we further separate θ into two parts: θ1 = βg, which is the scalar parameter of interest
(to be tested), and θ2 = (β
′
ng, α
′, η)(p−1)×1, which is the (p−1)×1 nuisance parameter. Then
the null hypothesis can be expressed as H0 : θ1 = βg = 0 and θ2 is arbitrary.
The biggest advantage of the score test in a GWAS setting is that one only need to
estimate the parameters once (under the null hypothesis), which is much less computationally
intensive as compared to likelihood ratio test or Wald test. This is because all the non-
genetic risk factors are the same for testing any of the SNPs. In addition, when minor allele
frequency (MAF) of the testing SNP is low, maximizing the complex log-likelihood under a
copula model (to obtain the parameter estimates) may produce unstable results. Therefore,
we propose to use score test for our problem.
Assume θˆ0 = (θ1 = 0, θ2 = θˆ20) is the restricted maximum likelihood estimate (MLE) of
θ from (2.5) under the restriction θ1 = 0, then the corresponding score function and Fisher’s
information can be written as
U(θˆ0) =
∂
∂θ
logL(D; θ)
∣∣∣∣
θ=θˆ0
= (U ′1(θˆ0), U
′
2(θˆ0))
′ = (U ′1(θˆ0), 0
′)′,
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where Uk(·) = ∂ logL/∂θk, k = 1, 2, and
I(θˆ0) = −E
[
∂2
∂θT∂θ
logL(D; θ)
]∣∣∣∣
θ=θˆ0
=
I11 I12
I21 I22
 ,
where I11, I12, I21 and I22 are partitions of the information matrix I by θ1 and θ2. Specifi-
cally, for single marker test, I11 is a scalar. By Cox and Hinkley (1979), we can obtain the
score test statistic as
Qs = U
′(θˆ0)I−1(θˆ0)U(θˆ0)
= (U ′1(θˆ0), 0
′)I−1(θˆ0)(U ′1(θˆ0), 0′)′
= U ′1(θˆ0)I11(θˆ0)U1(θˆ0),
where I11 = (I−1)11 = 1/(I11 − I12I−122 I21).
In practice, the observed information matrix J (θˆ0), where J (θ) = −∂2 logL(θ;D)∂θ′∂θ , is often
used in the score test. With bivariate copula models, the first and second order derivatives
of logL(D; θ) usually have very complex forms and the forms depend on the specific copula
model as well as the marginal distributions. Thus, we propose to use numerical differentiation
through Richardson’s extrapolation (Richardson, 1911) to approximate the score function
and observed information matrix, denoted by U˜ and J˜ . This numerical approximation only
requires a close-formed log-likelihood function. Therefore, the score test statistic we propose
is
Q˜s = U˜
T (θˆ0)J˜ −1(θˆ0)U˜(θˆ0) = U˜T1 (θˆ0)J˜ 11(θˆ0)U˜1(θˆ0), (3.1)
which asymptotically follows a χ21 distribution under the null. If P (χ
2
1 > Q˜s) < 0.05, we
reject H0 at the 5% level.
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3.2.1 Choices of marginal distributions
In this work, we assume the marginal distributions are from the PH family, which can be
written as
Sk(tki|xki) = P (Tki ≥ tki|xki) = S0k(tki)exp(xkiβk), k = 1, 2, i = 1, ..., n.
The corresponding hazard function for Tki given covariate Xki can be expressed as
λk(tki|xki) = λ0k(tki)exp(xkiβk), k = 1, 2, i = 1, ..., n, (3.2)
where λ0k(tki) is the baseline hazard function for the kth survival time. First, we consider
both parametric and weakly parametric assumptions for λ0k(·). For example, with Weibull
distribution,
λ0k(t) = γkλk(λkt)
γk−1, γk > 0, λk > 0, k = 1, 2,
or with Gompertz distribution,
λ0k(t) = γkλke
λkt, γk > 0, λk > 0, k = 1, 2,
where λk is the scale parameter and γk is the shape parameter for each baseline margin. In
this case, the full parameter set θ is (βg, βng, γk, λk, η).
In some circumstances, a specific parametric marginal distribution may not fit the data
properly. Kim et al. (2007) has shown that the association parameter estimation in copula
models is not robust to misspecification of the marginal distributions. Thus, a relaxed
weakly parametric assumption such as the piecewise constant hazards may be more desired
for marginal distributions. For example,
λ0k(t) = ρjk for t ∈ Ajk = (a(j−1)k, ajk], j = 1, ..., r, k = 1, 2,
where 0 = a0k < a1k < ... < ark = max yik are pre-specified cutoff points. The full parameter
set θ in this case will be = (βg, βng, ρjk, η).
In addition to parametric and weakly parametric model for marginal distribution, non-
parametric or semiparametric estimates of baseline hazard function are sometimes desired.
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For example, one can consider the Breslow estimator (Breslow, 1972) to treat λ0(·) as piece-
wise constants between all uncensored failure times. A pseudo-maximum likelihood (PML)
estimation can be implemented by fixing the cumulative baseline hazard Λ0k(t) with its
estimate from the marginal model.
For example, the Breslow estimator proposed by Breslow (1972) can be used by treating
λ0(·) as piecewise constant between uncensored failure times in the proportional hazards
model. In such a case, the Breslow estimator is
Λˆ0(t) = Σ
n
i=1
I(Ti ≤ t)∆i
Σj∈RieβˆXj
,
where Ti are ordered event times and Ri are observations still at risk.
3.2.2 Two-step estimation procedure
Note that, due to the form of most copula functions, the first and second derivatives of full
log-likelihood function are typically quite complex. For example, the cumulative density
function for Clayton copula (2.5) with respect to u and v is
cη(u, v) = (1 + η)(u · v)−1−η(u−η + v−η − 1)−
1
η
−2. (3.3)
In the Appendix, we derive the first and second order derivatives of Cη(u, v), which are
very complex. This may cause issues in both estimating speed and stability. In addition,
the analytical form is not reproducible when changing the copula function or the marginal
distribution specification.
Then by formula (2.5) and (3.3), under Cox PH assumption, we can derive the explicit
joint density function with covariates as
f(t1i, t2i|β, η, λ0) = (1 + η)×
[
S01(t1i)
exp(β1ix1i) × S02(t2i)exp(β2ix2i)
]−1−η
× [S01(t1i)−η exp(β1ix2i) + S02(t2i)−η exp(β2ix2i) − 1]− 1η−2 . (3.4)
In order to derive the above score test statistic in (3.1), we need to estimate θ under H0.
Motivated by the two-stage estimation approach from Shih and Louis (1995), we propose
a two-step maximum likelihood estimation procedure to obtain the restricted MLE θˆ0 =
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(0, θˆ20). In step 1, we first obtain initial estimates of the parameters in marginal distributions
(i.e., S0 and βng) based on marginal likelihood functions. Then we maximize the pseudo joint
likelihood (with the initial estimates of S0 and βng plugged in) to get an initial estimate of
the association parameter η. Then in step 2, we maximize the joint likelihood with the
estimates from step 1 being initial values to obtain final estimate of θˆ0. Detailed steps are
provided below:
(1) Obtain initial estimates of θ0:
a. (βˆ
(1)
ng , αˆ(1)) = arg max
(βng ,α)
logL0(βng, α), where L0 denotes the likelihood function under
marginal univariate data (without the genetic factor);
b. ηˆ(1) = arg max
η
logL(βˆ
(1)
ng , αˆ(1), η).
(2) Optimize the joint log-likelihood function of the bivariate data to get final estimates:
θˆ20 = (ηˆ, αˆ, βˆng) = arg max
(βng ,α,η)
logL(βng, α, η) with initial value (βˆ
(1)
ng , αˆ(1), ηˆ(1), ).
Standard two-step estimation procedure for copula models stops after step (1-ii), since the
association parameter η is of the primary interest. Note that, the initial estimates from step
(1) are already consistent and asymptotically normal (Shih and Louis, 1995). But one can-
not use Hessian matrices directly from step (1-i) and (1-ii) to obtain variance estimates for
(αˆ, βˆng). The second step produces correct variance covariance estimates for all the param-
eters using the joint likelihood. Our experience finds that, the performance of convergence
is greatly improved by using initial values from the first step.
For non-parametric baseline hazard function estimator, such as Breslow, one can obtain
consistent estimates for regression coefficients and the association parameter by treating
baseline hazards as nuisance parameters. However, the Hessian matrix from the PML in
step 2 cannot be directly used for estimating the variance of βˆ and ηˆ. One solution is to use
bootstrapped variance estimates, for example, see Lawless and Yilmaz (2011). Alternatively,
a sieve-based smoothing technique can be used to estimate the baseline hazards (He and
Lawless, 2003; Ding and Nan, 2011). In that case, the semiparametric M-estimation theory
applies and the variance estimates for βˆ and ηˆ can be obtained from the joint sieved log-
likelihood in step 2.
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3.2.3 Model selection
A crucial issue in applying the copula-based joint survival function to a given data set is
how to choose a suitable parametric copula. Different copula functions can lead to very
different dependence structures. Several model selection procedures have been proposed for
copula-based time-to-event model. The Akaikes Information Criteria (AIC) (Akaike, 1998)
and Bayesian Information Criteria (BIC) (Schwarz, 1978) have been widely used for model
selection purpose in copula models. Wang and Wells (2000) proposed a model selection
procedure based on nonparametric estimation of the bivariate joint survival function within
Archimedean copulas. However, it requires to obtain a consistent estimate of a nonparametric
bivariate joint survival function and its limiting distribution, which is often non-trivial in
practice. Later, Chen et al. (2010b) proposed a penalized pseudo-likelihood ratio test with a
two-step estimation approach for model selection under any parametric copula. To the best
of our knowledge, there is no package exists for either of these two approaches, so we simply
choose AIC statistics as our model selection criteria.
3.3 SIMULATION STUDIES
In this section, we evaluate the finite sample performance of the proposed test procedure
through various simulation studies and compare it to the Wald test under Cox PH model
with robust variance estimate (Lee et al., 1992). The Wald test from Cox model under
independence assumption is also included for type-I error control simulations.
3.3.1 Bivariate time-to-event data generation
Recall that the bivariate joint survival function under a copula model is specified as
S(t1, t2) = Cη(S1(t1), S2(t2)),
where U = S1(T1), V = S2(T2) each follows a uniform distribution U [0, 1]. Define Wv(u) =
h(u, v) = P (U ≤ u|V = v), which equals to ∂Cη(u, v)/∂v. To generate bivariate survival data
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(t1i, t2i), i = 1, .., n, we first generated vi and wi from two independent U [0, 1] distributions.
Then let wi = h(ui, vi)(= Cη(ui, vi)/∂vi) and solved for ui from the inverse of h function
h−1. Finally, we obtained t1i and t2i from S−11 (ui) and S
−1
2 (vi) respectively. We generated
censoring times c1i and c2i from uniform distribution U(0, C) with C chosen to yield censoring
rates of 50%.
The value for the association parameter η was chosen to introduce weak or strong associ-
ation, represented by Kendall’s τ = 0.2 and 0.6. We generated SNP data from a multinomial
distribution with values {0, 1, 2} and probabilities {p2, 2p(1− p), (1− p)2}, where p was the
MAF, chosen to be 40% or 5%. We also included a continuous non-genetic risk factor Xng,k
(k = 1, 2), generated from a normal distribution N(6, 22), where the mean and standard
deviation were decided based upon our AMD data.
In all simulations, the sample size was N = 500 and we chose the same baseline marginal
distribution for the two survival times (i.e., S01(t) = S02(t)). For type-I error control sim-
ulations, βg was set to be 0. We replicated 100,000 runs and evaluated the type-I error at
various α levels: 0.05, 10−2, 10−3 and 10−4, respectively. For power evaluation, we replicated
1000 runs under each SNP effect size. A range of βg was picked to represent weak to strong
SNP effect. For the situation when MAF = 0.4, βg varies from 0.05 to 0.3. While for MAF
= 0.05, βg varies values from 0.05 to 0.6.
3.3.2 Parameter estimation
First, we examined the estimation statistics for baseline hazard coefficients α = (λ, k), copula
association parameter η and genetic effect βg. Table 1 reports the results from the situation
where data were simulated from Clayton Weibull model. We fitted robust Cox, Clayton cop-
ula with Weibull, piecewise constant and Breslow margins models. Bootstrap variances were
calculated for Breslow margins model. For baseline hazard parameters, Clayton Weibull
model obtains good estimation accuracy at all settings. For βg, the robust Cox, Clayton
Weibull and Breslow margin models obtain more accurate estimates than the Clayton piece-
wise constant model. All four models achieve good coverage probabilities. For η, the Clayton
Weibull model obtains more accurate estimates than the Clayton piecewise constant model.
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Table 1: Estimation and inference statistics from Clayton copula models with different marginal distributions. True data were
simulated from Clayton copula with Weibull marginal distributions.
λ = 0.1 k = 2 η = 0.5 βng = 0 βg = 0
Bias SE SEE CP Bias SE SEE CP Bias SE SEE CP Bias SE SEE CP Bias SE SEE CP
Cox robust - - - - - - - - - - - - 0.0004 0.0241 0.0224 0.959 0.0015 0.0787 0.0740 0.938
Copula Weibull 0.0002 0.0075 0.0075 0.949 0.0092 0.0708 0.0722 0.956 0.0055 0.1237 0.1225 0.953 0.0005 0.0214 0.0213 0.960 0.0018 0.0763 0.0721 0.939
Copula PW - - - - - - - - 0.0390 0.1323 0.1313 0.947 0.0005 0.0208 0.0213 0.964 0.0024 0.0851 0.0830 0.955
Copula Breslow - - - - - - - - 0.0086 0.1239 0.1267 0.957 0.0004 0.0227 0.0222 0.945 0.0016 0.0744 0.0724 0.943
λ = 0.1 k = 2 η = 3 βng = 0 βg = 0
Bias SE SEE CP Bias SE SEE CP Bias SE SEE CP Bias SE SEE CP Bias SE SEE CP
Cox robust - - - - - - - - - - - - 0.0006 0.0226 0.0224 0.952 0.0010 0.0936 0.0868 0.930
Copula Weibull 0.0001 0.0055 0.0055 0.955 0.0110 0.0784 0.0774 0.946 0.0172 0.333 0.336 0.951 0.0004 0.0120 0.0123 0.960 0.0022 0.0754 0.0710 0.932
Copula PW - - - - - - - - 0.0223 0.3583 0.3683 0.939 0.0004 0.0114 0.0120 0.962 0.0018 0.0733 0.0713 0.947
Copula Breslow - - - - - - - - -0.0251 0.3586 0.3648 0.935 0.0003 0.0157 0.0166 0.958 0.0024 0.0851 0.0830 0.955
λ = 0.1 k = 2 η = 0.5 βng = 0 βg = 0.5
Bias SE SEE CP Bias SE SEE CP Bias SE SEE CP Bias SE SEE CP Bias SE SEE CP
Cox robust - - - - - - - - - - - - 0.0011 0.0214 0.0207 0.942 0.0019 0.0757 0.0699 0.936
Copula Weibull 0.0003 0.0069 0.0070 0.9444 0.0072 0.0661 0.0664 0.937 0.0024 0.1113 0.1106 0.944 0.0013 0.0194 0.0193 0.949 0.0015 0.0715 0.0673 0.937
Copula PW - - - - - - - - 0.0457 0.0122 0.0120 0.945 0.0003 0.0186 0.0194 0.953 -0.0175 0.0697 0.0679 0.933
Copula Breslow - - - - - - - - 0.0041 0.1141 0.1125 0.946 0.0008 0.0208 0.0203 0.942 0.0014 0.0690 0.0735 0.934
λ = 0.1 k = 2 η = 3 βng = 0 βg = 0.5
Bias SE SEE CP Bias SE SEE CP Bias SE SEE CP Bias SE SEE CP Bias SE SEE CP
Cox robust - - - - - - - - - - - - 0.0030 0.0209 0.0206 0.950 0.0050 0.0880 0.0816 0.936
Copula Weibull 0.0001 0.0050 0.0050 0.943 0.0092 0.0736 0.0719 0.938 0.0138 0.3020 0.3085 0.953 0.0021 0.0100 0.0100 0.952 0.0034 0.0687 0.0654 0.952
Copula PW - - - - - - - - 0.2265 0.3379 0.3431 0.924 0.0001 0.0097 0.0095 0.961 -0.0151 0.0672 0.0662 0.950
Copula Breslow - - - - - - - - -0.0440 0.3357 0.3322 0.937 0.0028 0.0137 0.0130 0.964 0.0046 0.0806 0.0827 0.933
Number of replications = 1000, number of subjects = 500, censoring rate = 50%, MAF = 40%.
SE: standard deviation of the point estimate, SEE: mean of the standard error estimates, CP: 95% coverage probability.
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3.3.3 Computing time
Table 2: Computing time required for testing 1000 variants using different methods.
Model Time (second) Non-convergence runs (rate)
Cox Robust 12.23 11/1000 (1.1%)
Copula score 654.90 0/1000 (0 %)
Copula LRT 1272.90 0/1000 (0 %)
Copula Wald 1762.96 0/1000 (0 %)
* Number of subject =500, censoring rate =50%, MAF = 5%, Kendall’s τ = 0.6
** A binary covariate ∼ Bernoulli(0.5) is included in the marginal regression model
We performed a simulation study to get an estimate of the computing time required for
each method. True data were simulated from the Clayton copula with the Weibull margins
model. All derivatives from the copula model were numerically solved. Table 2 shows that
the Cox robust method is most computationally favorable. However, the convergence is an
issue for the Cox robust model as we can see from the table. The non-convergence rate for
the Cox robust model is 1.1%, which can be problematic when conducting a large number of
tests on a genome-wide scale. Other limitations of the Cox robust method will be discussed
in section 3.3.4. Within the copula framework, the score test used the least computing time
compared to LRT and Wald test. This is because, for the the LRT and the the Wald test,
we need to do parameter estimation under the alternative for each SNP. Specifically, for the
Wald test, it also needs to calculate the Hessian matrix under each alternative. For the score
test, although it needs to evaluate the score vector and the Hessian matrix for each SNP
numerically, it only requires to perform the parameter estimation under the null once.
3.3.4 Simulation I: correctly specified model
In this section, we evaluated the method performance under correctly specified models. The
true models are from the Clayton copula with the Weibull or Gompertz marginal distribu-
tions. With Weibull margin, we chose λ = 0.01 and γ = 2, and with the Gompertz margin,
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we chose λ = 0.2 and γ = 0.05. In both scenarios, we also fitted marginal distributions with
piecewise constant hazards.
Table 3 provides empirical type-I error rates under different α levels for four methods,
namely, (1) the Cox model under independence assumption, (2) the Cox model with robust
variance/covariance estimate, (3) the copula model with parametric marginal distributions
(either Weibull or Gompertz), and (4) the copula model with piecewise constant marginal
distributions. It is clearly seen that when MAF=40%, all the methods, except for the
independent Cox method, control the type-I error well. However, when MAF=5%, the
robust Cox method yields inflated type-I error rates at all α levels, especially when α level is
low. For example, with data generated from Clayton copula with Weibull margins, the type-I
error from the robust Cox method is 0.003 and 0.0007 for α = 0.001 and 0.0001, respectively,
which is 3 or 7 times of the expected value. The two copula methods control type-I error
very well under both common and rare allele frequency scenarios. The independent Cox
method always inflates the type-I error, which is not surprising.
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Table 3: Type-I error for testing the genetic effect at various α levels for the Clayton copula
with Weibull and Gompertz marginal distributions.
Kendall’s τ = 0.2 Kendall’s τ = 0.6
MAF α Cox-I Cox-R Cop-P Cop-PW Cox-I Cox-R Cop-P Cop-PW
Clayton Weibull
5%
0.05 0.084 0.062 0.052 0.044 0.141 0.063 0.053 0.046
0.01 0.022 0.016 0.011 0.009 0.053 0.017 0.012 0.009
0.001 0.0034 0.0029 0.0012 0.0009 0.0129 0.0030 0.0014 0.0010
0.0001 0.0007 0.0007 0.0001 0.0001 0.0035 0.0007 0.0002 0.0002
40%
0.05 0.086 0.054 0.052 0.045 0.142 0.055 0.053 0.046
0.01 0.023 0.012 0.011 0.009 0.054 0.012 0.011 0.009
0.001 0.0040 0.0015 0.0013 0.0008 0.0132 0.0014 0.0012 0.0009
0.0001 0.0007 0.0002 0.0001 0.0001 0.0033 0.0001 0.0001 0.00004
Clayton Gompertz
5%
0.05 0.083 0.061 0.053 0.044 0.138 0.062 0.053 0.044
0.01 0.022 0.016 0.011 0.008 0.051 0.016 0.011 0.009
0.001 0.0034 0.0029 0.0012 0.0009 0.0129 0.0030 0.0014 0.0010
0.0001 0.0006 0.0006 0.0002 0.0001 0.0032 0.0007 0.0002 0.0001
40%
0.05 0.084 0.054 0.052 0.044 0.140 0.054 0.052 0.044
0.01 0.023 0.012 0.011 0.008 0.053 0.012 0.011 0.008
0.001 0.0040 0.0015 0.0013 0.0008 0.0132 0.0014 0.0012 0.0009
0.0001 0.0007 0.0002 0.0001 0.0001 0.0036 0.0001 0.0002 0.0001
* Non-genetic effect includes a margin-specific continuous variable and a shared cluster-specific variable.
** Number of replications = 100,000. Sample size = 500.
*** Cox-I (Independent Cox), Cox-R (Robust Cox), Cop-P (copula with a parametric margin)
Cop-PW (coupla with a piecewise constant hazards margin).
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Figure 2: Simulation results for power comparison between robust Cox (Cox-R) model, copula models with parametric and
weakly parametric (i.e., piecewise constant) margins over different genetic effect sizes with 5% α level.
28
Figure 2 presents the power curves over different genetic effect sizes for the three meth-
ods: robust Cox, Clayton copula with Weibull margins, and Clayton copula with piecewise
constant margins. True models are under the Clayton copula with Weibull or Gompertz
margins (Replicates = 1000. Sample size = 500, censoring rate = 50%). We can see that
both copula methods yield better power as compared to the robust Cox method, especially
when the association is strong. The parametric copula method is slightly more powerful
than the weakly parametric copula model, which is as expected.
We also fitted the robust Weibull method for the case where the marginal distributions
are Weibull. The results (in terms of both type I error control and power) are very close to
the results from the robust Cox method and thus are omitted. Therefore, the inflated type-I
error issue when MAF is small exists in the robust parametric (marginal) method as well.
3.3.5 Simulation II, misspecified model
In this section, we evaluated the method performance in the situation of misspecification
of either the copula function or the marginal distributions. In the case of the copula func-
tion being misspecified, data were generated from a Gumbel copula with Weibull marginal
distributions where λ = 0.01 and γ = 2. For misspecification of the marginal distribution,
data were generated from a the Clayton copula with Gompertz distributions where λ = 0.2
and γ = 0.05. In both scenarios, data were fitted by Clayton copula with Weibull marginal
distributions or piecewise constant marginal distributions.
Table 4 provides type-I errors under different α levels for two misspecified scenarios. The
same four methods as in section 3.3.4 were compared. Under both scenarios, the two Cox
model approaches do not depend on copula model specifications (so long as the marginal
distributions are still from the PH family), and thus yield similar performance as those un-
der correct model specification cases. When copula function is misspecified, the parametric
copula model shows an obvious inflation on type-I errors, especially when the association is
strong. Copula model with piecewise constant margins shows a smaller degree of inflation
of type-I error rates. When marginal distributions were misspecified, the parametric copula
shows a conservative type-I error control. The copula model with piecewise constant mar-
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gins is robust against incorrectly specified marginal distributions. Therefore, our proposed
method depends on correctly specified copula model, and thus, model selection (diagnostics)
is recommended in real data analysis.
3.4 APPLICATION ON AREDS DATA TO IDENTIFY RISK VARIANTS
FOR AMD PROGRESSION
3.4.1 AREDS data analysis
We applied our methods to the Age-related Eye Disease Study (AREDS) data. AREDS
was a multi-center, controlled, randomized clinical trial sponsored by National Eye Institute
(Age-Related Eye Disease Study Research Group, 1999). It was designed to assess the clinical
course of, and risk factors for the development and progression of AMD. Participants in this
study were followed up to 12 years, with scheduled visits every 6 months. In our research,
we are interested in identifying genetic variants that are associated with progression to late
AMD. It has been known that the progression profiles of two eyes are correlated.
The study collected DNA samples of consenting participants centrally by the Interna-
tional AMD Genomics Consortium (Fritsche et al., 2016) and performed genome-wide geno-
typing. The Illumina platform with a custom-modified HumanCoreExome array was used
to obtain the genotypes. Then imputation was performed using the 1000 Genomes Project
reference panel (Phase I). Traditional genotypes data are set to values of 0: no minor allele;
1: one copy of the minor allele; 2: two copies of the minor allele. Here we use dosage data
that is continuous and can be any number between 0 and 2. The final data set includes
8,974,355 SNPs (265,096 genotyped and 8,709,259 imputed SNPs).
We analyzed a subset of 629 Caucasian participants who have at least one eye in moderate
AMD stage at baseline. For the purposed of saving computing time, we use this subset of
data that is considered more at risk for analysis in this section. The time-to-progression
was calculated for each eye of these participants. The overall censoring rate was 54% for
our analysis sample. In this work, we specifically tested the common variants (i.e. SNPs
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Table 4: Type-I error at various α levels with misspecified copula models. Data are generated
from a) Clayton copula with Gompertz margin or b) Gumbel copula with Weibull margin.
Kendall’s τ = 0.2 Kendall’s τ = 0.6
MAF Tail Cox-I Cox-R Cop-P Cop-PW Cox-I Cox-R Cop-P Cop-PW
Misspecification of margin
5%
0.05 0.085 0.063 0.032 0.043 0.142 0.063 0.032 0.043
0.01 0.023 0.016 0.005 0.008 0.053 0.017 0.005 0.009
0.001 0.0035 0.0030 0.0003 0.0007 0.0133 0.0034 0.0014 0.0008
0.0001 0.0006 0.0006 < 0.0001 0.0001 0.0035 0.0007 0.0002 0.0001
40%
0.05 0.085 0.054 0.031 0.042 0.142 0.054 0.053 0.043
0.01 0.024 0.012 0.005 0.008 0.053 0.012 0.005 0.009
0.001 0.0041 0.0015 0.003 0.0007 0.0142 0.0016 0.0004 0.0008
0.0001 0.0008 0.0002 < 0.0001 0.0001 0.0037 0.0002 < 0.0001 0.0001
Misspecification of copula
5%
0.05 0.079 0.060 0.058 0.049 0.134 0.060 0.096 0.067
0.01 0.021 0.015 0.014 0.011 0.049 0.015 0.030 0.018
0.001 0.0035 0.0030 0.003 0.0007 0.0133 0.0034 0.0143 0.0008
0.0001 0.0007 0.0005 0.0003 0.0003 0.0035 0.0005 0.0017 0.0007
40%
0.05 0.077 0.052 0.056 0.048 0.133 0.052 0.092 0.064
0.01 0.020 0.011 0.012 0.009 0.048 0.011 0.027 0.015
0.001 0.0041 0.0015 0.0031 0.0007 0.0142 0.0016 0.0042 0.0071
0.0001 0.0005 0.0001 0.0009 0.0001 0.0025 0.0001 0.0009 0.0002
* Clayton copula with Weibull margin was fitted as the Copula parametric (Cop-P) model in both scenarios.
** Clayton copula with piecewise constant hazards margin (Cop-PW) was also fitted in both scenarios.
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with MAF ≥ 5%) from chromosome 1 and 10, since some of the most significant regions
associated with AMD risk (i.e., the CFH and ARMS2 gene region) is on chromosome 1
and 10. In total, we analyzed around 840,000 SNPs.
To decide which non-genetic risk factors to include in the regression model, we performed
univariate analysis using both Clayton copula with a Weibull margin model and the robust
Cox model (Table 5). Variables with a univariate pvalue < 0.05 were considered as co-
variates in the multivariate copula model. The baseline severity score, age and the current
smoker category had significant univariate p-values from both copula and robust Cox mod-
els. Although smoking has been known as a major risk factor for AMD, in this analysis, we
did not include smoking in the multivariate model, for two reasons: 1) the current smoker
group only accounted for 5% of the total sample, 2) computing time will be greatly increased
with two more covariates. The treatment effects were adjusted by baseline AMD severity
score to accommodate the stratified randomization (participants with less severe AMD at
baseline were only randomized to placebo or antioxidants alone arms) (Age-Related Eye
Disease Study Research Group, 1999). Therefore, the non-genetic risk factors we included
are baseline age and baseline AMD severity score. The AMD severity was calculated based
on centralized grading of stereoscopic fundus photographs. The severity score ranges from 1
to 12, with 12 being the most severe stage. Late AMD is defined as the severity score ≥ 9
(9: noncentral Geographic Atrophy (GA), 10: central GA, 11: Choroidal neovascularization
(CNV), and 12: CNV and central GA). For each eye that is free of late AMD at baseline,
the progression time is defined as the time (in years) from the baseline visit to the first visit
that the severity score reaches 9 or higher. If the eyes severity score does not exceed 9 during
the follow up, it is treated as censored with censored time defined as the last visit time.
To decide which copula function and which marginal distribution to choose for this
dataset, we used AIC, given by AIC = −2 logL(D; θˆ) + 2k, where k is the total number
of parameters in θ0. Specifically, we considered two copula functions, Clayton and Gumbel,
and three marginal distributions: Weibull, Gompertz and piecewise constant.
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Table 5: Univariate analysis for risk factors of progression-to-late-AMD using the Clayton
copula model with Weibull margins.
Variable Mean(SD)/N(%) HR (95% CI)** p (copula) p (CoxRst)
Baseline age (year) 69.55 (5.23) 1.03 (1.01, 1.05) 2.6× 10−3 2.9× 10−4
Sex
Male 269 (43%) Reference
Female 360 (57%) 1.20 (0.97, 1.44) 0.07 0.16
Baseline smoking
Never 272 (43%) Reference
Former 324 (52%) 1.15 (0.96, 1.32) 0.13 0.14
Current 33 (5%) 1.86 (1.32, 2.62) 3.5× 10−4 1.6× 10−3
Education
≤ high school 223 (35%) Reference
> high school 406 (65%) 0.85 (0.71, 1.01) 0.06 0.08
Baseline severity score 5.81 (1.27) 1.59 (1.46, 1.73) 3.3× 10−25 4.6× 10−50
Treatment*
Placebo 149 (24%) Reference
Antioxidants only 159 (25%) 0.81(0.64, 1.03) 0.09 0.37
Zinc only 157(25%) 1.13 (0.89, 1.45) 0.31 0.77
Antioxidants + zinc 164 (26%) 0.98 (0.77, 1.24) 0.85 0.99
*Treatment effect is adjusted by baseline AMD severity score
**Hazard ratio is computed based on a Clayton copula with a Weibull margin
*** CoxRst: Cox robust model with adjusted variance estimates
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3.4.2 Data analysis results
Table 6 presents the AIC values for each model under the null hypothesis with non-genetic
risk factors only. The Weibull marginal distribution under both copula models produced
similar AIC values, which are smaller than other AIC values. We performed analyses using
both Gumbel and Clayton copulas and their results are very similar. We presented the
results from Clayton copula (with Weibull margin), given the computation time for the
Clayton copula is much faster than for the Gumbel copula.
Table 6: The AIC values for the candidate models under null hypothesis with non-genetic
risk factors only (i.e., baseline age and baseline severity scores).
Marginal Dist. Clayton copula Gumbel copula
Weibull 4442.524 4441.449
Gompertz 4485.848 4463.890
Piecewise Constant 4544.953 4508.787
Table 7 presents the 10 top significant (independent) variants discovered from our analysis
or known variants associated with AMD disease risk. The variant rs10922109 is a known
common variant associated with AMD disease risk from the CFH region with MAF = 28%.
Note that, the known variant rs10922109 from CFH on chromosome 1 does not rank within
the top 10 in this sub-population GWAS result. It still has a small p-value of 3.3×10−4 with
our proposed method. The variant rs2672599 is another known common variant associated
with AMD disease risk from the ARMS2/HTRA1 region with MAF = 35% respectively. For
SNP rs2672599 the estimated effect size (i.e., Hazard Ratio) for this SNP is 1.42, with a
95% CI = [1.23, 1.65]. Fig. 4(a) is the marginal (eye-level) Kaplan-Meier (K-M) plot, which
shows this variant can separate AMD progression curves quite well. The p-values from the
copula-based method are slightly smaller than those from the robust Cox model for most of
those 10 SNPs.
Figure 3 shows Manhattan plots for all variants with MAF ≥ 5% on chromosome 10
tested by robust Cox model and Copula Weibull model respectively. The Manhattan plots
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Table 7: The p-values from robust Cox and Clayton copula with Weibull margins for the
10 top SNPs on chromosome 1 and 10.
SNP Gene BP MAF CoxRst ClaytonWeibull
CHROMOSOME 1
rs12083705 KMO 241,715,015 0.09 7.1× 10−7 2.0× 10−5
rs74960672 PLXNA2 209,019,110 0.05 7.8× 10−6 1.6× 10−6
rs5003371 CHI3L2 111,784,260 0.08 7.8× 10−5 2.7× 10−6
rs2206514 PTCHD2 11,642,294 0.33 6.4× 10−5 4.5× 10−5
rs12757114 LOC10012913 105,670,026 0.47 2.4× 10−5 8.5× 10−7
CHROMOSOME 10
rs72798393 LOC101928913 67,031,293 0.09 3.3× 10−5 5.5× 10−7
rs73292512 C10orf11 78,171,701 0.05 2.4× 10−5 8.5× 10−7
rs2672599 ARMS2/HTRA1 124,211,625 0.35 2.1× 10−5 2.7× 10−6
rs2284665 HTRA1 124,226,380 0.33 8.4× 10−5 3.0× 10−6
rs10828143 SLC39A12 18,338,012 0.15 4.6× 10−5 5.1× 10−5
* Bolded regions are known regions associated with AMD prevalence
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suggest that our proposed copula method obtains more signals compared to Cox model. In
either method, none of the SNPs achieves a p-value < 10−8, which is a commonly accepted
GWAS significance level. Using the suggestive GWAS level of 10−5, on chromosome 10, there
are 58 variants with p < 10−5 identified from the copula-based approach, while no variants
with p < 10−5 identified from Cox robust method on chromosome 10. On chromosome 1,
neither methods has identified variant with p-value < 10−8, while there are 15 variants with
p-value < 10−5 using the Clayton copula with Weibull margin and 7 variants when using the
robust Cox model.
In addition to the test results for each variant, we can obtain both estimated joint and
conditional survival functions from the copula model with Wald test on variants of interest,
which can be used to establish a predictive model for progression-free probabilities. For
example, Fig. 4(b) plots the joint 5-year progression-free probability contours (i.e, neither
eye is progressed by year 5) for subjects having the same baseline severity score (=5.8) and
age (=69.6) but different genotypes of the variant rs2672599. Fig. 4(c) plots the conditional
5-year progression-free probability of the remaining years for one eye, given the other eye has
been progressed at year 5. It is clearly seen that in both plots, the three genotype groups
are well separated, with the AA group having the largest progression-free probabilities.
We further picked two variants, rs72798393 from gene LOC101928913 and rs2672599
from gene ARMS2, and plotted the predicted 5-year joint progression-free probabilities
by genotype group, varying the eye-level baseline severity score values (Fig. 5). We can
see that carrying more T allele of rs72798393 leads to larger progression-free probabilities,
indicated by the overall lighter color of the plot, while carrying more C allele of rs2672599
leads to smaller progression-free probabilities, indicated by the overall darker color of the
plot. Within each genotype group, having a larger baseline severity score leads to smaller
progression-free probabilities.
Moreover, in Fig.6, we plotted the predicted joint progression-free probability function
P (t1,i−1 < t1 < t1,i, t2,i−1 < t2 < t2,i) by varying the values for (t1,i−1, t1,i, t2,i−1, t2,i) for sub-
jects in different genotype groups of rs2672599. It is clearly seen that the joint progression-
free probabilities decrease as the years increase, with smaller overall probabilities in subjects
carrying more C alleles. We can also see that the two eyes are more likely to progress within
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Figure 3: Manhattan plots of − log10(p-value) for all common variants (MAF > 5%) on
chromosome 10 from the AREDS data.
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the similarly years, observed by the darker color cloud around the diagonal lines, which
indicates the two eyes are correlated in terms of progression.
38
Figure 4: The estimated AMD progression profiles by a top SNP rs2672599 (ARMS2 )
(a) The eye-level K-M plot, with the total number of eyes and the percent of progressed eyes in each genetic group given; (b)
The copula-based estimated joint progression-free probability contours (the baseline severity score and age are fixed at their
mean values: 5.8 and 69.6, respectively); (c) The estimated conditional progression-free probabilities of remaining years (since
year 5) for one eye, given the other eye has been progressed by 5 year (the baseline severity score and age are also fixed at
their mean values: 5.8 and 69.6, respectively).
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Figure 5: Predicted joint 5-year progression-free probabilities P (T1 > 5, T2 > 5) for subjects with mean age 70 and baseline
severity scores between 4 and 8 for both eyes, separated by genotype group of rs72798393 (gene: LOC101928913) and rs2672599
(gene: ARMS2), respectively.
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Figure 6: Predicted joint progression-free probabilities P (t1,i−1 < t1 < t1,i, t2,i−1 < t2 < t2,i) for subjects in different genotype
groups of rs2672599 (gene: ARMS2). The baseline severity score and age are fixed at their mean values: 5.8 and 69.6,
respectively.
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Finally, to evaluate the model fitting, we plotted the estimated baseline hazard function
from the copula model and displayed it on top of the K-M estimated baseline hazard function.
Figure 7 shows that the two curves agree well with each other, indicating the Weibull margin
with Clayton copula fits the data well. The estimated association parameter η is 1.23, which
corresponds to Kendall’s τ = 0.38. This implies that there exists moderate association
between the progression time of the two eyes.
Figure 7: Estimated baseline hazard function from the Clayton copula with Weibull margins
model and the empirical K-M hazard function estimates
3.5 DISCUSSION
Here we developed a computationally efficient copula-based score test procedure for large-
scale bivariate time-to-event data. The copula model provides flexibility in modeling the
association and marginal distributions separately. The score test procedure, as compared
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to the other likelihood-based tests, has significant benefit in computation speed for the
GWAS setting that we consider here. The proposed method has been demonstrated to be
stable, with correct type-I error control and satisfactory power performance when the model
assumptions are met.
Compared to the Cox model with robust variance estimates, which is frequently used in
analyzing multivariate survival data, our copula-based method is more powerful when model
is correctly specified. Moreover, our method is more suitable for testing low MAF variants
as compared to robust Cox model in terms of type-I error control. Lastly, in our real data
analysis, the robust Cox approach failed to converge in some situations when the MAF is
low, while our copula-based approach was stable and unaffected by MAF.
Several directions may be pursued to extend the current proposed approach. First, as we
have observed from our simulations, the performance of the proposed method is not robust
against the misspecification of the copula function. Instead of using one-parameter copula
functions as we consider here, one may consider using a two-parameter copula function,
which is more flexible for characterizing the dependence structure of the bivariate data. For
example, Chen (2012) have introduced a framework for estimating two-parameter copula
models. In that setting, the association is described by two parameters in the copula function,
with one to characterize the upper tail dependence and the other one to characterize the
lower tail dependence. Both Clayton and Gumbel copulas are two limiting scenarios of the
two-parameter copula family.
Secondly, we can further relax the assumption on marginal distribution to allow non-
parametric or semiparametric estimates for the baseline hazard functions. We have exam-
ined the estimation performance using Breslow estimator for the baseline hazards function.
Besides, one may consider relax the proportional hazards assumption to accelerated model
or proportional odds models.
Lastly, in our AREDS data, the actual time-to-late-AMD is interval censored, due to
intermittent assessment times (which were pre-determined in the trial). We currently treat
them as right censored data given the interval lengths are fairly small and similar for all
subjects. However, it is worthwhile to extend this test procedure to handle bivariate interval-
censored data. All these directions are currently under investigation.
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The application of the proposed method on AREDS data jointly modeled the progression
profiles in both eyes, which, to the best of our knowledge, has not been done in any of the
previous studies on AMD progression. The findings provided new insights about the genetic
causes on AMD progression, which will be critical to establish novel and reliable predictive
models of AMD progression to accurately identify high-risk patients at early stage. Our
proposed methods are applicable to general bilateral diseases and are particularly useful for
performing tests across a large number of biomarkers.
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4.0 GENE-BASED TESTS FOR BIVARIATE TIME-TO-EVENT DATA
THROUGH FUNCTIONAL REGRESSION
In genome-wide association studies, single variant test (SNP level) is very useful in detecting
possible signals across the whole genome. Typically, after top loci are detected in replication
studies, regions around top variants will then be fine-mapped to further evaluate the disease
loci. However, there are some limitations when applying single variant tests. First, with
each SNP been tested individually, due to its small effect size, it may suffer from an issue of
lacking power and multiple testing. Secondly, true causal SNPs may not be genotyped due
to the technology or cost reason. Instead, a SNP that is close to the true causal variant is
often captured. With partial linkage disequilibrium (LD), the observed effect size is likely to
be smaller. Furthermore, most statistical approaches used for single variant test are focused
on common variants and can be too liberal when minor allele frequency is low. For example,
we have identified in Chapter 3 that Cox model with robust variance adjustment leads to
an inflated type-I error when MAF is small. A threshold for MAF is commonly applied
when performing GWAS on single variants. In our single marker test scenario in Chapter 3
we applied a filter of MAF > 0.05 in all analyses. To solve these problems, there has been
increasing interests in developing gene-based tests in the genetic analysis, which can usually
take the LD information within a region into account and are suitable for collapsing a set of
variants with low MAF.
The statistical methods for gene-based association studies can be broadly classified as
burden tests, kernel-based association tests and functional linear model approaches, which
we have introduced in section 2.4.3. Such approaches have been extended to censored time-
to-event outcomes (Lin et al., 2011; Chen et al., 2014; Fan et al., 2016). It has been shown
that for quantitative, binary and censored traits, functional linear can be more powerful
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than SKAT type or burden test in many scenarios (Fan et al., 2013, 2014, 2016). The idea
of treating the effect of genetic variants as an unknown function of actual physical positions
in functional linear model utilizes the LD information among close variants.
Motivated by our research question on identifying associations between genetic markers
and AMD progression, in this chapter, we develop several test procedures using functional
regression (FR) for gene-based association analysis of bivariate censored traits.
4.1 COPULA-BASED FUNCTIONAL REGRESSION
4.1.1 Model specification
In order to perform tests on gene-based association analysis for bivariate time-to-event data,
an intuitive extension is to combine the copula test procedure from Chapter 3 with the Cox
functional regression model for censored traits as proposed by Fan et al. (2016).
Assume n individuals with m variants being sequenced for a genomic region. Physical po-
sitions for each variant within a region are denoted as 0 ≤ u1 < ... < um (which are typically
standardized into [0, 1]). Let Gi = (gi(u1), ..., gi(um))
′, gi(uj) ∈ (0, 1, 2), j = 1, ...,m denote
the genotypic information for the m variants, and (X1i, X2i) = ((x1i1, ..., x1ip); (x2i1, ..., x2ip))
denote a p× 2 matrix of fixed effect covariates for subject i.
The bivariate Cox functional regression model on hazard function can be written as
λki(t) = λk0(t) exp
(
X
′
kiβ +
∫ 1
0
Gi(u)γ(u)du
)
, k = 1, 2,
where λk0(s) is the baseline hazard function for kth margin, β is a p×1 vector of coefficients
for non-genetic fixed effect covariates, and γ(u) is the genetic effect function of Gi(u) at the
position u. We assume both γ(u) and Gi(u) are smooth functions.
Then for each margin, the corresponding marginal survival function under Cox functional
regression model is
Ski(t) = exp(−Λki(t)) = exp
(
−
∫
λki(t)dt
)
= exp
(
−
∫
λk0(t) exp
(
X
′
kiβ +
∫ 1
0
Gi(u)γ(u)du
)
dt
)
. (4.1)
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4.1.2 The genetic variant function Gi(u)
If the genotype data are of good quality with low missing rate, we can simply utilize the
observed genetic information to represent Gi(u). For example, we can use the raw genotype
data as proposed in (2.10),
Gˆi(u) = Gi = (gi(u1), ..., gi(um))
′.
If genotype data have a fairly high missing rate, we may apply an ordinary linear square
smoother to obtain a continuous realization for discrete Gi. Let
φ(u) = (φ1(u), ..., φBx(u))
′, k = 1, ..., Bx,
be a series of basis functions (e.g, B-spline or Fourier spline basis). Denote by Φ the m×Bx
matrix with elements φb(uj). Then through a linear square smoother (Ramsay et al., 2009),
we can write an estimate of GVF Gˆi(u) as:
Gˆi(u) = (gi(u1)), ..., gi(um))Φ[Φ
′
Φ]−1φ(u). (4.2)
If missingness occurs,
Gˆi(u) = (gi(u1)), ..., gi(um′))Φ˜[Φ˜
′
Φ˜]−1φ(u),
where (gi(u1)), ..., gi(um′)) are observed non-missing genotypes and Φ˜ is the corresponding
basis matrix evaluated at observed genotypes.
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4.1.3 The genetic effect function γ(u).
The GEF γ(u) is an unknown smooth function with an arbitrary form that we need to
estimate. To do this one can expand it into a linear combination of basis functions and
coefficients. Define a series of Bγ basis function by ψ(u) = (ψ1(u), ...ψBγ (u))
′ and a Bγ × 1
vector γ = (γ1, ..., γBγ )
′, then γ(u) can be approximated by
γˆ(u) = (ψ1(u), ...ψBγ (u))(γ˜1, ..., γ˜Bγ )
′
. (4.3)
Similarly, choices of ψi(u) can be B-spline or Fourier basis. A standard test procedure to
test whether the variants in a region are associated with the outcome can be translated to
the null hypothesis:
H0 : γ1 = ... = γBγ = 0.
4.1.4 Functional regression for hazard function
Depending on whether or not to smooth the GVF within the hazard function, we propose
two types of functional regression models. The first approach is to smooth both G(u) and
γ(u). Replace G(u) and γ(u) by expression in (4.2) and (4.3), we can have the Cox PH
model formulated as:
λki(t) = λk0(t) exp
(
X
′
kiβ + (gi(u1), ..., gi(um))Φ[Φ
′
Φ]−1γ
∫ 1
0
φ(u)ψ(u)du
)
= λk0(t) exp(X
′
iβ +M
′
iγ), (4.4)
where M
′
i = (gi(u1), ..., gi(um))Φ[Φ
′
Φ]−1
∫ 1
0
φ(u)ψ(u)du. The integral
∫ 1
0
φ(u)ψ(u)du can be
readily calculated using R package “fda” (Ramsay et al., 2009).
Another approach is to smooth γ(u) only. In this formulation, we use
Gi = (gi(u1), ..., gi(um))
′
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as a discrete approximation of G(u) and only replace GEF with (4.3):
λki(t) = λk0(t) exp
(
X
′
kiβ +
[∑m
j=1(gi(uj)× (ψ1(uj), ..., ψBγ (uj))
]
(γ1, ..., γBγ )
′
)
= λk0(t) exp(X
′
iβ +M
′
iγ), (4.5)
where M
′
i =
∑m
j=1 gi(uj)× (ψ1(uj), ..., ψBγ (uj)) is a fully observed term.
As mentioned before, two common basis functions are the B-spline and the Fourier spline.
The B-spline basis (de Boor, 2011) is a series of non-periodic functions with polynomial
segments joint at values called knots. The segments have specifiable smoothness across every
breaks. Advantages of applying the B-spline basis are its fast computation feature and great
flexibility in structure. The Fourier splines consist of a set of periodic functions, with the
basis function Φ1(u) = 1, Φ2r(u) = cos(2piru) and Φ2r+1(u) = sin(2piru), r = 1, ..., (Bγ−1)/2
(de Boor, 2011).
4.1.5 Bivariate functional regression under copula framework
In this work, the obtained genotype data from AREDS have passed strict quality control
procedures and with no missings. Thus we do not smooth the GVF and use the observed Gi
value for Gi(u). So we only smooth the GEF. Note that, instead of estimating m parameters
for m variants, we have only Bγ ( m in most cases) parameters to estimate.
Recall that the bivariate joint survival function under a copula model can be written as
a function of two marginal survival functions,
S(t1, t2) = Cη(S1(t1), S2(t2)), t1, t2 ≥ 0. (4.6)
Combine (4.1) and (4.6), we can write out the bivariate survival function with functional
regression on marginal survival functions as:
Si(t1i, t2i) = Cη
(
exp
(
−
∫
λ10(t) exp
(
X
′
1iβ +
∫ 1
0
Giγ(u)du
)
dt
)
,
exp
(
−
∫
λ20(t) exp
(
X
′
2iβ +
∫ 1
0
Giγ(u)du
)
dt
))
.
Joint likelihood function L can be written out in similar style as in (2.5)
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4.1.6 Score test
Now define the new parameter set θ = (γ, β, α, η) and θ0 = (γ = 0, β, α, η), where α =
(S01, S02) are parameters in marginal proportion hazards model. Denote by θ1 = γ the
parameters of interest and θ2 = (β, α, η) the nuisance parameters. To test for association
between the m genetic variants and the survival trait, the null hypothesis can be expressed
as
H0 : γ = (γ1, ..., γBγ )
′ = 0. (4.7)
Note that, unlike the single marker test in Chapter 3, we are now simultaneously test a
vector of parameters.
The corresponding score function and Fisher’s information can be written as
U(θˆ0) =
∂
∂θ
logL(D; θ)
∣∣∣∣
θ=θˆ0
= (U ′1(θˆ0), U
′
2(θˆ0))
′ = (U ′1(θˆ0), 0
′)′,
where θˆ0 is the maximum likelihood estimator of θ under the restriction θ1 = γ = 0 (a
Bγ > 1 dimension vector of zeros), Ul(·) = ∂ logL/∂θl, l = 1, 2, and
I(θˆ0) = −E
[
∂2
∂θT∂θ
logL(D; θ)
]∣∣∣∣
θ=θˆ0
=
I11(θˆ0) I12(θˆ0)
I21(θˆ0) I22(θˆ0)
 ,
with I11, I12, I21 and I22 being partitions of the information matrix I by θ1 and θ2.
Qs = U
′
1(θˆ0)I11(θˆ0)U1(θˆ0),
where U ′1(θˆ0) is a Bγ×1 vector and I11 = (I−1)11 = (I11−I12I−122 I21)−1 is a Bγ×Bγ matrix.
Similar numerical approximation techniques from Chapter 3 are used for this score test
approach. We use observed information matrix J (θˆ0), where J (θ) = −∂2 logL(θ;D)∂θ′∂θ , to approx-
imate the information matrix. Then apply Richardson’s extrapolation (Richardson, 1911)
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to approximate the score function and observed information matrix, denoted by U˜ and J˜ .
Therefore, the score test statistic we propose is
Q˜s = U˜
T (θˆ0)J˜ −1(θˆ0)U˜(θˆ0) = U˜T1 (θˆ0)J˜ 11(θˆ0)U˜1(θˆ0), (4.8)
which asymptotically follows a χ2Bγ distribution with Bγ degrees of freedom under the null.
We reject H0 at the 5% level if P (χ
2
Bγ
> Q˜s) < 0.05.
4.1.7 Likelihood ratio test
Different from the single marker test case, where the computing efficiency is a key factor for
deciding the test procedure, we have many less tests in gene-based scenario (∼ 20K genes in
the whole genome). Therefore, an alternative approach is to perform likelihood ratio test,
in addition to the score test.
With full log-likelihood function L(θ), the likelihood ratio test statistic can be written
as:
Ql = −2(L(θˆ0)− L(θˆ)), (4.9)
where L(θˆ) is the the unrestricted maximum likelihood value and L(θˆ0) is the restricted
maximum likelihood with θ1 = γ = 0. Ql also follows a χ
2
Bγ
distribution with degrees of
freedom Bγ and we reject H0 at the 5% level if P (χ
2
Bγ
> Ql) < 0.05.
4.2 FUNCTIONAL REGRESSION WITH COX ROBUST MODEL
In Chapter 2, we have mentioned the marginal model is a popular approach for handling
dependence. Adapting the idea of marginal model, we can construct a Wald type test with
a robust variance-covariance estimator as proposed by Lee et al. (1992) under the functional
linear model framework. The null hypothesis is the same as (4.7).
51
Define U(γ) to be the partial score vector under the marginal Cox PH model, we can
modify formula (2.2) and get the partial score function under functional linear model as:
U(β, γ) =
2∑
k=1
n∑
i=1
Uki(β, γ)
=
2∑
k=1
n∑
i=1
∆ki

Xki
Gi
− S(1)k (tki; β, γ)
S
(0)
k (tki; β, γ)

=
2∑
k=1
n∑
i=1
∆ki

Xki
Gi
−
∑n
p=1 Ykp(tki) exp(X
′
kpβ + (GpΨ(u))
′γ)
Xki
Gi

∑n
p=1 Ykp(tki) exp(X
′
kpβ + (GpΨ(u))
′γ)

,
(4.10)
where Yki(t) = I{Tki ≥ t}, Ψ(u) is a m × Bγ matrix with element ψb(uj) for the bth basis
function evaluated at the jth variant. Define (βˆ, γˆ) to be the root of U(β, γ) = 0. If the
marginal Cox regression model is correctly specified, n−
1
2U(γ) is asymptotically normally dis-
tributed with mean zero. The variance covariance matrix can be estimated by the “sandwich
estimator”
Γˆ(γˆ) = Aˆ(γˆ)−1Bˆ(γˆ)(Aˆ(γˆ)−1)′,
where Aˆ(γˆ) = − 1
2n
∑2
k=1
∑n
i=1 ∂Uki(γˆ)/∂γ|γ=γˆ and Bˆ(γ) = 1n
∑2
k=1
∑n
i=1 U
2
ki(γ)|γ=γˆ.
A Wald type of test can be performed using this adjusted variance covariance matrix
Γˆ(γ)
Qw = γˆΓˆ
−1(γˆ)γˆ
′ ∼ χ2Bγ . (4.11)
Lee et al. (1992) has showed that Qw in (4.11) asymptotically follows a χ
2 distribution with
degrees of freedom Bγ.
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4.3 SIMULATION STUDIES
In this section, we performed simulation studies to evaluate the performance of the proposed
copula-based functional regression model. In our simulations, variants with MAFs less equal
to 0.05 are considered as rare. Two scenarios were considered: (1) some causal variants are
rare and some are common; (2) all causal variants are rare. We report the results of copula-
based functional regression score and LRT test, functional regression with robust variance
adjustment, univariate functional regression model, SKAT and burden test (from R package
SeqMeta (Voorman et al., 2016)).
4.3.1 Data generation
Genetic data were generated from European ancestry of 10,000 haplotypes covering 1Mb
regions, simulated by Yun Li at the University of North Carolina, Chapel Hill. Calibrated
coalescent model as programmed in COSI was used to generate the haplotypes with linkage
disequilibrium (LD) information (Schaffner et al., 2005). With 10,000 haplotypes, first we
decided a genetic region of length 6 Kb and 30 Kb for all and rare only variants scenarios.
For both all variant and rare only scenarios, the regions contains around 20 variants. A
random mating technical was then applied to generate genetic information for n subjects.
In our simulation, we simulated 100 genetic datasets with a population of size 1000. For
each genotype set, K replicates of bivariate survival times were generated using the same
copula conditional distribution technique from section 3.3.1. Such approach lead to a total
100 × K genotype-phenotype datasets and is similar to the SKAT paper of (Chen et al.,
2014), which made comparison between methods more valid.
In this simulation study, we included one non-genetic effect, which was normal distributed
with mean 6 and standard error 2. Bivariate event times were generated from a Clayton
Weibull model with scale parameter λ = 0.1, rate parameter k = 2. A uniform distribution
[0, c] was used to generate censored times, where c was chosen to yield a censoring rate of
50%.
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4.3.2 Type-I error
In type-I error analysis, marginal association levels corresponding to Kendall’s τ = 0.05, 0.4,
0.8 were evaluated. The marginal regression model was generated from
S(tki) = exp{−(λtki)keX′kiβ},
where β is the coefficient (chosen to be 0) for the non-genetic covariate.
Table 8 presents type-I error results for testing both common and rare variants (MAF >
1%) in a region. It shows that when two margins are close to independent, i.e. Kendall’s τ =
0.05, all approaches obtain accurate type-I error rates. With association level increases, type-
I error for Cox model under the independent assumption inflates quickly. The Cox robust
method has slightly inflated type-I error rates. The copula-based models achieve good type-
I error control rates at all association levels, despite the choice of spline. Within copula
framework the score test and LRT obtain similar performance. However, such inflation does
not increase with the association level.
Table 9 presents the type-I error results for testing only rare variants (MAF ∈ [1%, 5%])
in a region. The overall performance for the rare variant only situation is similar to the
all variants scenario. Robust Cox FLM model are observed to have an inflation in type-I
error rates, while all copula-based tests control the type-I error well at all nominal levels.
Therefore, we can conclude that our proposed copula based methods are more suitable for
testing rare variants.
4.3.3 Empirical power
In power analysis, we generated data evaluating both homogeneous genetic effects, i.e., genes
with effect of the same direction, and heterogeneity genetic effects, i.e., genes with effects of
opposite directions. The marginal regression model was generated from
S(tki) = exp{−(λtki)keX′kiβ+G′iγ},
where γ = (γ1, ..., γBγ ) are the coefficients for causal variants, G = (G1, ..., Gs) are s
causal variants. The effect size for each causal variant was chosen to be c |log10MAF |
2
, where
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Table 8: Type-I error at various association levels from Clayton copula with Weibull margins
for both common and rare variants.
Copula FR Cox FR SKAT Burden
Kendall’s τ α level Copula-score Copula-LRT CoxFLM-ind CoxFLM-single CoxFLM-Rst (Single) (Single)
τ = 0.05
0.05 0.0547 0.0524 0.0673 0.0523 0.0626 0.0494 0.0492
0.01 0.0114 0.0102 0.0152 0.0104 0.0150 0.0099 0.0105
0.001 0.0014 0.0012 0.0020 0.0012 0.0022 0.0012 0.0010
0.0001 0.00015 0.00010 0.00033 0.00018 0.00047 0.00009 0.00010
τ = 0.4
0.05 0.0527 0.0522 0.2119 0.0515 0.0653 0.0504 0.0495
0.01 0.0105 0.0103 0.0832 0.0104 0.0162 0.0099 0.0099
0.001 0.0011 0.0011 0.0214 0.0012 0.0025 0.0011 0.0010
0.0001 0.00015 0.00012 0.00521 0.00010 0.00047 0.00009 0.00012
τ = 0.8
0.05 0.0534 0.0521 0.3293 0.0526 0.0628 0.0511 0.0500
0.01 0.0110 0.0105 0.1644 0.0107 0.0159 0.0101 0.0097
0.001 0.0011 0.0011 0.0594 0.0010 0.0021 0.0012 0.0011
0.0001 0.00012 0.00014 0.02103 0.00010 0.00042 0.00013 0.00012
Simulation setting: number of subjects = 1000, MAF > 1%, censoring rate = 50%, number of basis = 5, replication = 100,000
Copula-score: Score test using copula-based Cox proportional hazards functional linear model
Copula-LRT: likelihood ratio test using copula-based Cox proportional hazards functional linear model
CoxFLM-ind: LRT using Cox proportional hazards functional linear model treating two margins as independent
CoxFLM-single: LRT using Cox proportional hazards functional linear model using collapsed univariate cluster level data
CoxFLM-Rst: Wald test using Cox proportional hazards functional linear model with robust variance covariance adjustment
SKAT (single): SKAT with bivariate margins collapsed into univariate cluster level data
Burden (single): burden test with bivariate margins collapsed into univariate cluster level data
c = 0.4, 0.3, 0.25 for scenarios of 10%, 20% and 30% of causal variants in a given region,
respectively.
Methods we compared include: subject level LRT using Cox FLM, subject level tests
using SKAT, and burden tests, eye level Cox FLM with robust variance adjustment (Wald
test), Copula model using Cox FLM score test, Copula model using Cox FLM LRT.
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Table 9: Type-I error at various association levels from the Clayton copula with Weibull
margins for rare variants.
Copula FR Cox FR SKAT Burden
Kendall’s τ α level Copula-score Copula-LRT CoxFLM-ind CoxFLM-single CoxFLM-Rst (Single) (Single)
τ = 0.05
0.05 0.0539 0.0540 0.0690 0.0516 0.0677 0.0490 0.0500
0.01 0.0115 0.0118 0.0160 0.0105 0.0175 0.0094 0.0099
0.001 0.0011 0.0011 0.0021 0.0010 0.0035 0.0009 0.0010
0.0001 0.00014 0.00011 0.00030 0.00010 0.00135 0.00010 0.00009
τ = 0.4
0.05 0.0541 0.0537 0.2151 0.0521 0.0674 0.0499 0.0505
0.01 0.0113 0.0110 0.0855 0.0110 0.0173 0.0099 0.0101
0.001 0.0013 0.0012 0.0226 0.0011 0.0032 0.0008 0.0011
0.0001 0.00012 0.00012 0.00628 0.00010 0.00063 0.00014 0.00011
τ = 0.8
0.05 0.0534 0.0517 0.3305 0.0519 0.0646 0.0502 0.0502
0.01 0.0110 0.0101 0.1671 0.0112 0.0151 0.0103 0.0104
0.001 0.0011 0.0010 0.0609 0.0012 0.0022 0.00091 0.00010
0.0001 0.00012 0.00006 0.02122 0.0001 0.00035 0.00010 0.00008
Simulation setting: number of subjects = 1000, MAF ∈ [1%, 5%], censoring rate = 50%, number of basis = 5, replication = 100,000
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Figure 8: Empirical power analysis for 1000 gene regions at various association levels with both common and rare variants
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Figure 8 presents the power bars over different association levels and genetic effect sizes
for all variants (MAF > 1%). Overall, we see bivariate methods achieve higher power than
any univariate approaches. When association is strong, the copula-based test achieves better
power than the robust Cox FLM method, indicating that the Cox robust method tended to
be slightly conservative. We also note that, when there are heterogeneous genetic effects in
a region, the power of burden test decreases significantly.
Figure 9 shows the power analysis over different association levels and genetic effect sizes
using only rare variants (1% < MAF < 5%). We see that when variants are rare, within
univariate methods, the Cox FLM is not superior to the SKAT or burden test. Especially,
SKAT is very powerful for both cases of homogeneous and heterogeneous genetic effects.
However, with bivariate approaches incorporated by either copula or robust method, power
increases significantly and our proposed methods beat univariate SKAT/burden in most of
cases.
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Figure 9: Empirical power analysis for 1000 gene regions at various association levels with rare variants only
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4.4 REAL DATA ANALYSIS
4.4.1 AREDS data analysis
We applied our proposed methods on AREDS dataset (Age-Related Eye Disease Study
Research Group, 1999) to identify gene regions that are associated with AMD progression.
Detailed information about AREDS has been described in Chapter 3.
We included all Caucasian participants with neither eye progressed at the time of en-
rollment into the study. For bivariate approaches, time-to-progression was defined for each
eye. For univariate approaches, we collapsed eye-level data into subejct level and calculated
time to first eye progression as the progression time. A total of 2296 subjects were included
in the analysis. The baseline age and severity score (on a continuous scale ranged from 1 to
8) were included in the regression part as non-genetic risk factors.
Table 10 presents top 4 genetic regions associated with AMD risk identified by single
marker GWAS results in Fritsche et al. (2016). Therefore, we specifically examined these four
regions with our methods. Location of gene regions are extracted based on GRCh37/hg19
assembly from UCSC genome broswer. Variants within +/ − 5Kb of the region boundary
were included in the analysis.
To be consistent with singler marker analysis in Chapter 3, we also fit a Clayton copula
with Weibull margins in this gene-based analysis. B-spline functions were used to smooth
the genetic effect function. The number of basis is usually decided by the total number
of observations or through cross validation. In survival analysis it is related to the total
number of events. In our analysis, we examined the scenarios with number of basis equals 5,
6 and 7. We compared our 3 methods: copula functional linear model based score test and
likelihood ratio test, functional linear model with robust variance adjustment, with subject
level univariate functional linear model from Fan et al. (2016), SKAT and burden test. For
subject-level analysis, the phenotype data were defined as time to the first progressed eye.
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Table 10: Top gene regions from single variant GWAS results
Region Chr StartPos** EndPos** Num all Num rare***
ARMS2 regions* 10 124,134,094 124,274,424 508 132
C2-CFB-SKIV2L 6 31,895,266 31,937,532 127 69
C3 19 6,677,846 6,720,662 296 49
CFH 1 196,621,008 196,716,634 261 52
* PLEKHA1,MIR3941,ARMS2,HRTA1
** Rare variant is defined by 1% ≤ MAF ≤ 5%
*** Regions are selected with reference start and end pos +/− 5K (hg19)
4.4.2 Data analysis results
In both analyses with all variants and rare variants, we do not observe a specific pattern in
p-values when varying the number of basis.
Table 11 presents result using all variants (including common and rare). Gene regions:
CFH, C2 and ARMS2 are all significant with small p-values. Notice that the proposed bi-
variate approaches, i.e., copula score, copula likelihood ratio and Cox robust method achieve
much smaller p-values than existing univariate approaches. For example, with 5 basis the
p-values of copula FLM for ARMS2 regions are 1.1 × 10−4 and 1.0 × 10−4 with score test
and LRT respectively. For Cox FLM with robust variance estimate, the p-value is slightly
larger (6.4 × 10−3). While for unvariate anslysis, Cox FLM achieves a p-value of 0.09.and
neither SKAT or burden test reaches significance at α level of 0.05.
Table 12 presents the results using rare variants only to assess the genetic association with
progression. We discover the p-values are larger than the cases with all variants. However,
with only rare variants of MAF ∈ [0.01, 0.05], our method can still identify most top regions
as significant. The p-values from the bivariate copula-based methods and Cox robust FLM
are also smaller than those univariate approaches.
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Table 11: Bivariate functional regression results from AREDS data for top regions with both
common and rare variants
Copula FR Cox FR SKAT Burden
Gene basis number CopFLM-score CopFLM-lrt CoxFLM-Rst CoxFLM-single (Single) (Single)
CFH
5 1.4× 10−9 2.8× 10−10 6.4× 10−7 3.7× 10−5 0.03 2.2× 10−3
6 3.5× 10−9 7.0× 10−10 1.5× 10−6 8.4× 10−5 0.03 2.2× 10−3
7 1.1× 10−8 2.2× 10−9 4.1× 10−6 1.8× 10−4 0.03 2.2× 10−3
C3
5 0.06 0.06 0.04 1.8× 10−3 0.05 0.94
6 0.12 0.13 0.08 4.1× 10−3 0.05 0.94
7 0.10 0.10 0.06 2.1× 10−3 0.05 0.94
C2
5 1.6× 10−5 1.2× 10−5 3.9× 10−4 0.01 0.02 0.04
6 1.6× 10−5 1.3× 10−5 3.5× 10−4 0.02 0.02 0.04
7 3.3× 10−5 2.8× 10−5 7.0× 10−4 0.01 0.02 0.04
ARMS2
5 1.1× 10−4 1.0× 10−4 6.4× 10−3 0.09 0.10 0.31
6 1.5× 10−6 1.8× 10−6 4.1× 10−4 1.8× 10−3 0.10 0.31
7 5.4× 10−4 2.7× 10−4 9.9× 10−3 0.02 0.10 0.31
4.5 DISCUSSION
In this chapter, we extend the bivariate single variant test from Chapter 3 to gene-based
test using the idea of the functional linear model. On one hand, under the functional linear
model, the genetic effect can be viewed as a function of the physical positions of variants. On
the other hand, the copula model can effectively handle the correlation between the margins.
Combining FLM and the copula model will make it suitable for gene-based test on bivariate
time-to-event data. In addition, we extend the univariate FLM test and derive a robust
variance estimate (Liang and Zeger, 1986; Lee et al., 1992) for Wald test.
Extensive simulation studies were performed to evaluate the type-I error rates and power
performance for our methods. Both the score test and the LRT tests in the context of copula
FLM model control type-I error very well at all nominal levels. There is an noticeable
inflation of type-I error for the Cox FLM with robust variance estimate. Such inflation
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Table 12: Bivariate functional regression results from AREDS data for top regions with rare
variants (MAF ∈ [0.01, 0.05])
Copula FR Cox FR SKAT Burden
Gene basis number CopFLM-score CopFLM-lrt CoxFLM-Rst CoxFLM-single (Single) (Single)
CFH
5 6.8× 10−3 4.5× 10−3 5.6× 10−3 0.10 3.0× 10−3 0.76
6 8.4× 10−3 4.8× 10−3 8.7× 10−3 0.14 3.0× 10−3 0.76
7 2.6× 10−3 9.1× 10−4 3.6× 10−3 0.11 3.0× 10−3 0.76
C3
5 0.53 0.50 0.57 0.83 0.13 0.31
6 0.51 0.48 0.56 0.75 0.13 0.31
7 0.45 0.42 0.62 0.90 0.13 0.31
C2
5 4.3× 10−3 2.2× 10−3 0.02 0.16 0.12 0.01
6 8.7× 10−3 4.6× 10−3 0.03 0.23 0.12 0.01
7 1.5× 10−2 8.3× 10−3 0.05 0.29 0.12 0.01
ARMS2
5 1.1× 10−3 1.1× 10−3 8.4× 10−3 0.03 0.23 0.11
6 1.9× 10−3 1.4× 10−3 0.02 0.01 0.23 0.11
7 5.4× 10−4 2.7× 10−4 9.9× 10−3 0.02 0.23 0.11
has also been observed in single variant scenario when the MAF is small in Table 3. For
the power analysis, our bivariate tests show great advantage by utilizing all available data
without collapsing them into subject level. Power is greatly increased in both scenarios
that all causal variants are positive associated with phenotypes and causal variants have a
mixture of positive/negative effects.
The great advantage of proposed copula/Cox FLM models is the genetic effects are
treated as a function of the actual physical positions. Therefore, the LD information is
accounted in this method. On the contrary, SKAT and burden test do not depend on any
physical position. The test statistic for SKAT is a weighted sum of single marker score
statistics (Chen et al., 2014), which only models the pairwise LD between markers. Fan
et al. (2016) has demonstrated that FLM are more powerful than SKAT and the burden test
in many univariate cases.
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    We  also  applied our methods and the other existing methods (i.e., subject-level burden
test, SKAT, and FLM) on AREDS data to analyze genes in the whole genome to identify 
significant genes associated with AMD progression. Known AMD risk regions such as CFH 
and ARMS2 were identified as top genes from all methods. However, the genome-wide QQ-
plots and the genetic control indices indicate inflated type-I errors for all methods including 
the subject-level SKAT and burden test. Whether this is due to some strange region sizes (i.e., 
the number of variants) or violation of certain model assumptions in this AREDS data needs 
further examination. Therefore, the GWAS results were not presented in this dissertation. We 
will investigate this gene-based GWAS on AREDS data and publish our findings in the 
manuscript based on contents from Chapter 4.
To the best of our knowledge, the bivariate gene-based test for censored data has not been 
done in any previous studies. Specifically, the findings from AREDS data provided new 
perspective about the genetic causes on AMD progression, which will be valuable to establish 
novel and reliable predictive models of AMD progression. The proposed methods can be used 
for genome-wide association study of any bilateral disease to identify disease susceptible 
genes.
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5.0 CONCLUSION
The focus of this dissertation is to develop test procedures for genetic association analysis
with bivariate time-to-event traits. In the first part, we proposed a computationally efficient
score test for single variant that can be applied on genome-wide scale screening. In the second
part, we proposed several gene-based test procedures under the framework of functional linear
model. Our method can be applied to other bilateral diseases to identify genetic risk factors
for time-to-event outcome.
We implemented our proposed test procedures for bivariate time-to-event data into a
user friendly R package {CopulaTest}. The current version can handle both the score and
Wald test under Clayton or Gumbel copulas with parametric, weakly parametric or non-
parametric Cox PH margins. The gene-based test procedure will also be incorporated in the
package, which will make this tool comprehensive to perform genetic association analysis for
bivariate censored traits.
The work from Chapter 3 with copula-based score test for bivariate time-to-event data
has been submitted to Journal of Royal Statistics Society: Series C and was under review
at the time of dissertation submission. The manuscript is co-authored with Richard J Cook,
(Department of Actuarial Science, University of Waterloo), Wei Chen (Department of Pe-
diatrics, Children’s Hospital of Pittsburgh) and Ying Ding (Department of Biostatistics,
University of Pittsburgh).
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5.1 FUTURE WORK
Several extensions to this work can be considered. Most of them are driven by features of
our real data set.
First, the AREDS progression data are in fact interval-censored due to intermittent
assessment times. We treated them as right-censored given the assessment intervals (∼ 6
months) are relatively narrow compared to the entire follow-up time (12 years). However,
it is worthwhile to extend the methods to handle interval censored data since such type of
data often occur in practice. Thus extending our framework to make it suitable for interval
censored data will be natural to consider in the next step.
Secondly, the specification of marginal distributions in copula model can be further
relaxed. For example, one can consider the transformation model (Zhou et al., 2017) which
includes both proportional hazards model and proportional odds model as special cases.
Thirdly, in this dissertation, we are not able to handle subjects with one eye already
progressed at baseline. In real data analysis (AREDS), these subjects account for around
12% of the entire data. This data structure is a common phenomenon in bivariate censored
data. A mixture model with a composite likelihood function can be considered to handle
both two groups of subjects together: one with both margins and the other with only one
margin.
Another interesting extension can be the use of a two-parameter copula. We have ob-
served in Table 4 that misspecification on copula function can lead to serious problem in
type-I error control. Sometimes one-parameter copula may not be sufficient to model the
marginal dependence. With two parameters controlling both upper and lower dependence,
more complex dependence structure can be modeled.
The two-parameter copula in Archimedean family can be defined through a generator
function of the form
pk,η =
(
1
1 + sη
)k
, s ∈ [0,∞), 0 < η ≤ 1, k > 0. (5.1)
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In this family, one parameter k is used to capture lower tail dependence, defined as
τL = lim
v→1−
Pr(F2(T2) ≥ v|F1(T1) ≥ v),
and the other parameter η is used to characterize the upper tail dependence, defined as
τU = lim
v→0+
Pr(F2(T2) ≤ v|F1(T1) ≤ v).
Provided limits exist, τU ∈ [0, 1] and τL ∈ [0, 1], η and k have a one-to-one mapping with
the lower and upper tail dependence that τL = 2
−2k and τU = 2− 22η.
Both Clayton and Gumbel copulas are two limiting scenarios of the two-parameter copula
family. When η = 1, it degenerates to Clayton copula and when k → ∞, it becomes a
Gumbel copula.
In addition to extensions on the methodology part, a genome-wide analysis with the
smoking variable (perhaps collapsed into two categories: ever smoke and never smoke) added
(as an additional risk factor) to analyze the AREDS data would be worthwhile to perform.
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APPENDIX
EXACT ANALYTICAL DERIVATIVES FOR THE CLAYTON COPULA
Following, an exact analytical derivatives with respect to each margin for the Clayton Copula
will be derived. The purpose of this part is to show that how analytically complex for just
one type of copula function using exact form.
Clayton copula
Let A(u, v, η) = u−η + v−η − 1, then the copula density function w.r.t u, v is:
c(u, v; η) =
C(u, v; η)
∂u∂v
=
(u−α + v−η − 1)−1/η
∂u∂v
=
(1 + η)(u · v)−1−η
A(u, v, η)−1−
1
η
= (1 + η)(u · v)−1−η(u−η + v−η − 1)− 1η−2.
Now let’s look at the first derivatives of the function c(u, v; η) w.r.t u and η.
First derivative of c(u, v; η) w.r.t η
∂c
∂η
= (u, v)−η−1(u−η + v−η − 1)−2− 1η − (1 + η)(uv)−η−1ln(uv)(u−η + u−η − 1)−2− 1η+
(1 + η)(uv)−η−1(u−η + u−η − 1)−2− 1η(
ln(u−η + u−η − 1)
η2
+
(−2− 1
η
)(−u−ηln(u)− v−ηln(v))
u−η + u−η − 1
)
.
First derivative of c(u, v; η) w.r.t u
∂c
∂u
= (1 + η)(uv)−η−1(−η − 1)(u−η + v−η − 1)−2−η−1u−1
− (1 + η)η(−2− 1
η
)(uv)−η−1u−1−η(u−η + v−η − 1)3−η−1 .
68
Using the fact:
∂A
∂η
= −u−ηln(u)− v−ηln(v), ∂
2A
∂2η
= u−ηln(u)2 + v−ηln(v)2
and
∂A
∂u
= −ηu−η−1, ∂
2A
∂2u
= η(η + 1)u−η−2.
We have following second derivatives:
∂2c
∂2η
=
∂c
∂η
·
(
−ln(v) + ln(A(u, v, η))
η2
+
(−2− 1
η
)∂A
∂η
A(u, v, η)
)
+
c(u, v) ·
 ∂A∂ηA(u,v,η)η2 − 2ln(A(u, v, η))η
η4
+
(
1
η2
∂A
∂η
+ (−2− 1
η
)∂
2A
∂2η
)
· A(u, v, η)− (−2− 1
η
)
(
∂A
∂η
)2
A(u, v, η)2

∂2c
∂2u
=
∂c
∂u
(η + 1)u− (η + 1)c(u, v)
u2
+
(2 + 1
η
)
(
∂c
∂u
∂A
∂u
+ c(u, v)∂
2A
∂2u
)
− c(u, v)(2 + 1
η
)
(
∂2A
∂2u
)2
A(u, v, η)2
∂2c
∂uη
=
∂c
∂η
(η + 1) + c(u, v)
u
+
(uη+1A(u, v, η))
[
∂c
∂η
(2η + 1) + 2c(u, v)
]
u2η+2A(u, v, η)2
+
c(u, v)(2η + 1)
[
uη+1ln(u)A(u, v, η) + uη+1 ∂A
∂η
]
u2η+2A(u, v, η)2
∂2c
∂uv
=
∂c
∂v
(η + 1)
u
+
∂c
∂v
(2η + 1)
u2η+2A(u, v, η)
− c(u, v)(2η + 1)
uη+2A(u, v, η)2
× ∂A
∂v
.
With a specific marginal distribution function, we can derive complete analytical formulas
for each Clayton copula model.
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